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ABSTRACT 
Mantle cell lymphoma (MCL) accounts for 5-10% out of all Non-Hodgkin lymphomas 
(NHLs) and is one of the most aggressive forms of lymphomas with a median survival of 
less than 5 years. Currently, MCL is considered to be an incurable disease. 
 
MCL is characterized by the t(11;14)(q13;q32) CCND1/IGH translocation that results in 
high expression of cyclin D1. This translocation takes place at the pre-B cell stage and is 
generally recognized as the hallmark and primary oncogenic event in the evolution of 
MCL. Recently, the neural transcription factor SRY (sex-determining region Y) box 11 
(SOX11) gene was found to be expressed in over 90% of all MCLs. The SOX11 protein is 
not detected in the vast majority of other lymphomas or mature B-cells and its expression is 
independent of cyclin D1 status. Moreover, SOX11 has been proposed to have a functional 
role in the pathogenesis of MCL and may not only serve as a diagnostic biomarker. 
 
In this thesis, the functional role of the SOXC genes (SOX4, SOX11 and SOX12) have been 
studied in several different ways, both in MCL primary samples/cell lines and in non-MCL 
related cells with focus on the SOX11 gene. 
 
The SOXC transcription factors are known to compete for the same target genes. For the 
first time in MCL, the SOXC genes were quantified by qPCR in a set of MCL patients and 
MCL cell lines. As previously reported, SOX11 expression was high in MCL, but also 
SOX12 mRNA levels were found to be higher compared to non-malignant B-cells, whereas 
the expression levels of SOX4 varied. Further, expression of the SOXC genes correlated in 
SOX11 positive MCL (determined by immunohistochemistry). How SOX11 gene 
expression in MCL is regulated was also addressed by studying its promotor region. The 
promotor region of SOX11 was found to be hypomethylated in MCL patients and cell lines, 
but also in non-malignant B-cells indicating regulation by other epigenetic mechanisms 
than promotor methylation.   
 
Fast and accurate differentiation between similar entities of lymphoma is important since 
MCL has a more aggressive clinical course. Although having certain distinctive 
phenotypical markers, MCL and B-cell chronic lymphocytic leukemia/small lymphocytic 
lymphoma (B-CLL/SLL) are both CD19+, CD20+ and usually CD5+, which could 
complicate diagnosis by flow cytometry. We developed a method to accurately implement 
SOX11 in the diagnostic flow panel that consistently detected SOX11 protein in ex vivo 
isolated MCL cells, but not in CLL/SLL. When conjugated SOX11-antibodies are 
available, this method could be implemented in the clinic for CLL/SLL with aberrant 
immune phenotypes or rare cyclin D1- MCLs. 
 
The expression levels of SOX11 were further studied in a relatively large group of MCL 
patients (n=102) by qPCR to determine a cut-off for SOX11-negative MCL and to 
investigate how quantitative expression related to positivity/negativity by IHC. A cut-off 
was defined, which resulted in misclassification of only 2/102 by qPCR and IHC. However, 
for the IHC SOX11+ cases, the qPCR analysis was not able to find a natural cut-off that 
would identify cases with low expression. When grouping the samples based on expression 
(10% lowest expression versus the remaining cases), nodal disease was less frequent 
(p=0.01) and lymphocytosis more frequent (p=0.005) in the qPCR SOX11low-cases. 
Leukemic non-nodal MCL often expresses low levels of SOX11. The quartile of patients 
with the lowest SOX11 expression had significantly shorter overall survival in the group of 
patients who did not receive autologous stem cell transplantation. 
 
Studies were conducted in primary murine B-cells and a murine pro-B cell line to study 
Sox11 oncogenic potential and role in differentiation in early B-cells.  In the studied cell 
types, Sox11 did not per se act as an oncogene. Instead the rate of proliferation was reduced 
in the pro-B cell line and these cells changed morphology upon expressing the Sox11 gene. 
Gene expression analysis revealed upregulation of early cell cycle and cellular adhesion 
genes upon introduction of the Sox11 gene in the pro-B cells. Despite high similarity to 
Sox4 (important for B-cell survival and development), no obvious effect on selected B-cell 
differentiation stage associated genes were detected, which suggest that the effects of Sox11 
are context dependent and might differ in murine pro-B cells compared to MCL and during 
embryogenesis. 
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1 BACKGROUND 
1.1 B-CELL BIOLOGY 
Gnathostomes (vertebrates with jaws), the metazoan lineage to which humans belong, 
originated 500 million years ago together with our adaptive immune system [1]. The 
adaptive immune system includes B (bursa/bone marrow) and T (thymus) cells, whose 
purpose is to recognize and respond to different antigenic epitopes or toxins. The 
delineation of the B-cell and T-cell lineages began in 1965 with experiments by Cooper et 
al. conducted in chicken (hence the name bursa, a lymphoid organ in birds) [2].  
 
In humans, B-cells are derived from pluripotent hematopoietic stem cells (PHSCs). The 
hematopoietic system constantly generates a large number of specialized cell types from 
PHSCs with self-renewal potential. The PHSCs can give rise to all hematopoietic cells via 
sequential stages of differentiation described below (based on the following reviews [3, 4]). 
At each new stage, the progenitor cells encounter different binary choices from which they 
cannot return, and thus restrict their capacity to differentiate as they continue to progress 
through cellular development.  
 
Differentiated PHSCs become multipotential progenitors (MPPs). These cells are able to 
differentiate into either early lymphoid progenitors (ELPs) or common myeloid progenitors 
(CMPs). The transcription factor PU.1 (encoded by Spi1) has been shown to be an 
important regulator at this stage as Spi1-knockout mice die absent of B/T-cells, monocytes 
and granulocytes prior to birth [5]. The CMPs are limited to the myeloid or erythroid 
lineages and cannot differentiate into any lymphocyte lineage. The ELPs further 
differentiate into common lymphoid progenitors (CLPs) with the capacity of differentiating 
into B-cells, T-cells, dendritic cells (DCs) or natural killer (NK) cells. In the specific 
context of B-cell development, successful differentiation from CLPs into immature B-cells 
and more differentiated B-cells requires expression of several transcription factors to 
activate genes important for further differentiation, especially SOX4 [6], E2A [7], PAX5 
[8] and EBF [9]. Absence of these genes result in differentiation blockades at the pro/pre-B 
cell stage [10].  
 
Rearrangement of the immunoglobulin heavy chain (IGH) and the immunoglobulin light 
chain (IGL) gene segments by RAG1/2 occur at the pro-B cell stage after the late CLP 
stage. First is the recombination of the IGHD genes (diversity) to IGHJ genes (joining), 
which is followed by IGHV genes (variable) to IGHDJ, encoding the Ig μ heavy chain 
protein [11]. To validate that the Ig μ heavy chains are functional, a pre-B cell receptor 
(pre-BCR) is formed, constituted of the surrogate light chains λ5 and VpreB and the Ig μ 
heavy chain [12]. Successful pre-BCR complex formation leads to proliferation of the 
parent cell and the rearrangement of IGLV to IGLJ, encoding the κ or λ chains on the 
surface of the pre-B cell. The outcome of the IGHVDJ and IGLVJ rearrangement is an 
immature B-cell with a complete IgM displayed on the cell surface comprised of the Ig μ 
heavy chain and the κ or λ chain proteins. Subsequently, the newly formed immature B-
cells are selected not to react with self-antigens before permitted to access the blood 
circulation [13]. The cells gain access to primary lymphoid follicles where they start to 
mature and express IgD. At this stage, the transcriptional repressor BCL6 has an important 
function for germinal center (GC) formation, but also in preventing pre-mature activation 
and differentiation of B-cell in the GC [14]. 
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Formation of the GC starts in the lymphoid follicle when the mature naïve B-cells become 
activated by an exogenous antigen. Following interaction with T-cells in the T-cell zone of 
the follicle, the activated B-cells can either differentiate into short-lived plasma cells in the 
lymph node (usually those with high-affinity BCR) or long-lived memory B-cells. The GC 
is divided into two compartments, the dark zone (affinity maturation) and the light zone 
(selection). In order to generate high-affinity antibodies, the B-cells undergo somatic 
hypermutation (SHM) of the IGH and IGL and immunoglobulin isotype-switching by the 
DNA-editing deaminase enzyme AID. Upon proliferation and SHM in the dark zone, the 
cells enter the light zone where selection is based on BCR-affinity to the immunizing 
antigen.  
The B-cell can either encounter non-bound antigens or antigens presented on follicular 
dendritic cells (FDCs). The BCR binds and sequester free antigens into peptides before 
presenting them to T follicular helper cells (TFH-cells) on the surface in the context of its 
MHC-II complex. Hence, survival signals to the B-cells are provided by MHC-II and TFH-
cell interaction and interaction with the antigen presenting FDCs and the BCR. High 
affinity of the BCR to the antigen results in outcompeting those B-cells with lower affinity 
in binding to FDCs and higher concentration of peptides presented on the surface to TFHs, 
generating more survival signals. Thus, the B-cells with the highest BCR affinity survive 
and are selected. These can either re-enter the dark zone for further SHM or differentiate 
into memory B-cells or plasma cells [15, 16]. Exit from the GC occurs from the light zone 
and is mainly promoted by reduction of BCL6. The plasma cell differentiation program is 
induced by the transcription factors BLIMP1, XBP1 and IRF4, resulting in the subsequent 
repression of BCL6 and PAX5 [14]. 
There are several lymphomas that arise from B-cells. A cancer derived from a B-
lymphocyte is referred to as a B-cell lymphoma. The B-cell lymphomas often resemble 
specific stages of B-cell differentiation with respect to morphology, phenotype and gene 
expression profile, as illustrated for a selection of lymphomas in Figure 1. 
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  Figure 1:  A selection of B-cell lymphomas derived from different stages of B-cell development (partially 
modified from Kuppers, R., Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer, 2005. 5(4): p. 
251-62). 
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2 MANTLE CELL LYMPHOMA 
2.1 BACKGROUND 
Mantle cell lymphoma (MCL) was first described as centrocytic lymphoma (CCL) in the 
early 1970s according to the Kiel classification (updated classification [17]).  
 
MCL was originally considered to be exclusively stemming from naïve B-cells expressing 
CD5. However, newer findings now suggest that subsets of MCLs are derived from 
antigen-experienced B-cells [18-21]. Based on morphology, it was difficult to differentiate 
CCL from several closely related Non-Hodgkin lymphoma’s (NHLs), especially 
intermediate lymphocytic lymphoma (ILL)/lymphocytic lymphoma of intermediate 
differentiation (IDL)  [22]. CCL and ILL/IDL were defined as a B-cell neoplasms 
consisting of small to medium sized lymphoid cells similar to centrocytes or cleaved 
follicular center cells [23] making the two entities very similar.  
 
A breakthrough in recognizing MCL came after the discovery of the t(11;14)(q13;q32) 
CCND1/IGH translocation that results in overexpression of cyclin D1. Based on 
morphological, immunological and molecular data, Banks et al. [24] proposed the 
collective term mantle cell lymphoma (MCL) for CCL and several of its highly similar 
entities since they were all found to overexpress cyclin D1. MCL is also the term used by 
The World Health Organization (WHO) lymphoma classification [23].  
 
Cyclin D1 was fundamental in facilitating differential diagnoses of MCL from 
morphologically similar lymphomas, but also exposing the vast morphological spectrum of 
the disease. This breakthrough in diagnosis of MCL was much later followed by discovery 
that the transcription factor SRY (sex-determining region Y) box 11 (SOX11) is 
overexpressed in more than 90% of all MCLs. Importantly, SOX11 expression is not 
detected in highly similar lymphomas and its expression is independent of cyclin D1 [25, 
26]. 
 
2.2 MORPHOLOGICAL SUBTYPES 
MCL have three different growth patterns: nodular, diffuse and mantle zone growth pattern 
[23]. Currently, based on cytology, there are four different variants of MCL recognized: 
classical, small cell, blastic/blastoid and pleomorphic (mantle zone; diffuse variant) [27] 
(reviewed in [28]). Classical MCL is frequently defined by small to medium sized 
lymphoid cells with irregular nucleus and dispersed chromatin structure; the small cell 
subtype is defined by small round lymphocytes, clumped chromatin and high resemblances 
to chronic lymphocytic leukemia (CLL); the aggressive blastoid variant is defined by high 
mitotic rate and their resemblance to lymphoblasts, and the pleomorphic subtype is 
characterized by often apparent nucleoli and cleaved nuclei [23, 28]. 
 
2.3 PHENOTYPE 
In addition to cyclin D1+ and SOX11+ and intense expression of IgM and/or IgD, MCL 
cells express the following B-cell markers: CD19, CD20, CD22, CD79a, CD5, CD24, 
CD43, FMC7 and BCL2, but are generally negative for CD10, CD11c, CD23, BCL6 and 
CD200 [23, 28].  
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2.4 CELLULAR ORIGIN 
2.4.1 Immunoglobulin status 
Based on the large number of cases with unmutated IGHV, intense expression of IgM 
and/or IgD, CD5+ expression and mantle zone growth, the corresponding counterpart for 
MCL was hypothesized to stem from pre-germinal center naïve B-cells [29]. However, this 
concept has recently been challenged [18, 19, 21, 30, 31]. MCL has also been proposed to 
stem from a mature B-cell population discovered in human tonsils [32]. The subpopulation 
could be an intermediate of naïve and GC cells (IgD+CD38−CD23−FSChiCD71+). This 
particular subpopulation is mostly CD5-, whereas classical MCL is mostly CD5+.  
 
Not all MCLs are completely antigen-inexperienced with unmutated IGHV. Based on 
established cut-off values (>2% difference from germ line identity), roughly 75% of all 
cases were unmutated [18]. However, when applying a more stringent criterion (not having 
a single somatic hypermutation) for defining unmutated MCL on the very same cases, 
merely 29.5% (238/807) were truly unmutated (TU) [18]. This was confirmed in later 
studies, resulting in 24% (43/177) and 31.5% (40/127) to be TU MCL cases [33, 34]. 
Navarro et al. [33] further reported enrichment in naïve B-cell signatures for TU compared 
with enrichment in memory B-cell signatures for highly IGHV mutated cases.  
 
2.4.2 Epigenetics 
The methylation profile of MCLs can also provide information to better understand 
different subpopulations. Although the two subgroups, one GC-inexperienced (ranging 
from naïve B-cells to pro-GC B-cells with low frequency of SHM) and one GC-
experienced population, revealed by genome-wide DNA methylation were very 
heterogeneous it clearly reflected two distinct entities of MCL. [21]. Similar to previous 
studies with TU definition of IGHV for MCL [18, 33, 34], the majority of MCLs 
demonstrated a DNA methylation pattern more similar to that of antigen-experienced cells.  
 
Another study [35] implemented epigenetics to delineate the cellular origin of MCL by 
comparing it to normal naïve and GC-experienced B-cells. Briefly, the study demonstrated 
that the epigenetically defined regions of open chromatin (H3K36me3, H3ac, and 
H3K4me1) for naïve B-cells and GC-experienced B-cells had a highly significant overlap 
with the corresponding gene expression profiles that distinguish MCL and Burkitt 
lymphoma (BL, a GC-experienced lymphoma). The genes with higher/lower chromatin 
marker expression in naïve B-cells corresponded to higher/lower expression for the same 
genes in MCL, suggesting that the cellular counterpart of the MCL likely is naïve B-cells. 
 
2.5 DISEASE PRESENTATION 
MCL only accounts for 5-10% out of all NHLs, but it is one of the most aggressive forms 
of lymphomas, mainly in older men [19, 36-38]. It is characterized by rapid relapse after 
treatment and resistance to therapy. An overview of the disease development is outlined in 
Figure 2. At diagnosis, the neoplastic cells are often already disseminated into lymph 
nodes, peripheral blood, bone marrow, spleen and the gastrointestinal tract (GI) [39, 40]. 
Patients with primary disease presentation in the lymph nodes (classical MCL) have 
significantly lower survival compared to primary appearance in the extra nodal sites (non-
nodal MCL), such as the GI, head or neck and hematologic/reticuloendothelial systems 
(bone marrow and/or spleen) was emphasized in a recently published study [41]. Upon 
disease onset, the median survival is generally less than 5 years [42] with the most 
aggressive blastoid variant of MCL comprising 20–30% of all diagnosed cases [43]. 
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Classical MCL can evolve into blastoid MCL and blastoid MCL can relapse as classical 
MCL; however, de novo blastoid MCLs still constitute the majority of cases [44]. 
 
Currently, MCL is considered to be an incurable disease; however, there are subsets of 
MCLs that exhibit a more indolent disease with longer survival and no need for immediate 
treatment [45-48]. This subgroup can constitute up to 30% of all MCLs [49]. According to 
the latest WHO classification of lymphoid neoplasms [50], there are now two separate 
indolent subtypes; in situ mantle cell neoplasia (ISMCN) and the leukemic non-nodal MCL 
(nnMCL). ISMCN is characterized by cyclin D1+ cells situated at the inner mantle zone of 
follicles of otherwise healthy lymph nodes or tissue, which very infrequently can evolve 
into classical MCL [51]. The classical aggressive MCL involves the lymph node, often 
express SOX11, and is associated with an aggressive disease progression (developing to 
blastoid or pleomorphic). In contrast, nnMCL often involves peripheral blood, bone 
marrow and occasionally the spleen and is considered to be more indolent.  It is 
characterized by longer survival, hypermutated IGHV, low genetic complexity, 
downregulation of cell adhesion genes and genes of DNA damage repair pathways. This 
subtype is also often found to have low expression of SOX11 (reviewed by Jares et al. 
[52]). However, nnMCL can progress to an aggressive form after genetic alterations of 
TP53 [53], and of importance, not all indolent MCLs are associated with low expression of 
SOX11 [54].  
 
 
 Figure 2: Proposed model for the pathogenesis of the different subtypes of MCL (modified from conceptual image 
in Swerdlow, S. H. et al, Blood, 2016. 127(20): p. 2375-90). 
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2.5.1 Cyclin D1 in MCL 
Initially termed B-cell leukemia/lymphoma 1 (BCL1) based on the assumption of an 
oncogene existing at that locus, the t(11;14) BCL1/IGH breakpoint was first cloned from a, 
retrospectively, misdiagnosed CLL in 1984 [55]. It was later discovered that the active 
transcript of 11q13 cloned from parathyroid adenoma encoded a new G1 cyclin, denoted 
cyclin D1 (CCND1) [56], and subsequently it was established that CCND1 corresponds to 
the BCL1 gene [57]. Cyclin D1 promotes the transition from G1/S phase into S-phase and 
when gained at the pre-B-cell stage, the t(11;14)(q13;q32) translocation is generally 
regarded as the hallmark and primary oncogenic event in the evolution of MCL [58]. By 
this translocation the CCND1 gene becomes juxtaposed to the immunoglobulin heavy chain 
Eμ enhancer, resulting in aberrant cyclin D1 expression. Infrequently, the CCND1/IGH 
fusion gene is also amplified in MCL which has been associated with higher proliferation 
and worse clinical outcome [59, 60].  
 
The intricacy of cyclin D1 in MCL increased after reports suggested that cyclin D1 may be 
involved in chromatin remodeling and chromosome stability, as well as having a role in 
supporting DNA repair. Reports of deletion of the E2F inhibitor RB1 further indicate 
potential for a wider function of cyclin D1 than merely overcoming the G1/S phase [61].  
2.5.1.1 Cyclin D1 isoforms 
Cyclin D1 exists as two forms, isoform a and isoform b [62].  
 
The canonical cyclin D1 (isoform a) is a 36 kDa protein encoded by a mRNA transcript 
existing in two different lengths, 4.5 kb and 1.5 kb long, respectively. The 4.5 kb transcript 
encompasses a destabilizing 3’-UTR region allowing miRNAs to anneal, which leads to a 
reduced half-life compared to its truncated counterpart; 30 min compared with 3 hours [63].  
 
Next-generation sequencing (NGS) data has provided a more detailed mutational status in 
MCL and uncovered that specific hotspots in the 3’-UTR region of exon 1 on CCND1 are 
mutated in 14-34% of all investigated cases [64, 65], which could prevent binding of 
miRNA. The longer half-life of the shorter or mutated transcript consequently resulted in 
increased cyclin D1 protein expression in the investigated MCLs [66]. Data from MCLs 
expressing the shorter CCND1 transcript also correlated to a more aggressive disease 
progression [63, 66-68]. Furthermore, this isoform has been associated with ibrutinib 
(inhibits the function of Bruton's tyrosine kinase) resistance in MCL patients [69]. 
 
The second isoform, cyclin D1b, is less frequent and deficient of the C-terminal domain 
that partly regulates nuclear export. Despite a potentially higher protein accumulation in the 
nucleus, this isoform has never been considered of great importance in the pathogenesis of 
MCL due its very moderate expression levels [70, 71]. Further reasons for cyclin D1b not 
outcompeting cyclin D1a when expressed in MCL are their highly similar half-life and 
distribution in the cell [72]. To be noted, retention of cyclin D1 in the nucleus is oncogenic 
in vivo as shown by a cyclin D1 mutant mimicking the truncated cyclin D1b isoform [73]. 
However, cells carrying the t(11;14) translocation can be found in the blood of healthy 
individuals not developing MCL, indicate that additional genetic aberrations are required to 
develop MCL [74, 75].  
2.5.2 Cyclin D1-negative MCL 
Albeit aberrant cyclin D1 expression is considered to be one of the principal features of 
MCL, there are MCLs that are negative for cyclin D1. These types of cases can now better 
be identified by SOX11 expression. 
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The importance of implementing gene expression profiling (GEP) in MCL was emphasized 
when investigating a rare group of difficult to classify lymphoma cases. Although negative 
for cyclin D1, they otherwise shared similar morphological, molecular and clinical 
characteristics as conventional cyclin D1+ MCL. The GEP-studies performed on these rare 
cyclin D1- lymphoma cases demonstrated that they shared secondary genetic alterations 
similar to those found in cyclin D1+ MCL (in addition to the observed clinical and 
molecular manifestations) [76, 77]. The notion that this rare subgroup of cyclin D1- cases 
actually could constitute a separate entity within MCL was further corroborated in a large 
study of 40 cyclin D1- cases diagnosed as MCL. Among the cyclin D1- MCLs, the CCND2 
translocation was the most frequent chromosomal rearrangement resulting in high 
expression of cyclin D2 [77-85] (only one case has been reported for CCND3 translocation 
[85]).  
 
2.5.3 Secondary genetic aberrations 
Classical MCL acquires a high degree of genomic aberrations and is characterized by 
genomic instability. The (11;14)(q13;q32) translocation is essential for the initiation of the 
disease, however, cyclin D1 expression is not per se oncogenic as it has been detected in up 
to 1-2% of healthy individuals [86]. Further, knockdown of cyclin D1 has only minor 
effects on proliferation and survival in MCL cell lines [87]. Moreover, transgenic mice 
models overexpressing the most frequent isoform of cyclin D1 required additional 
oncogenic hits, such as MYC, to develop a B-cell lymphoma [88, 89]. Highlighted in 
several reviews ([19, 36, 52, 58, 90, 91]), genetic deletions, mutations or amplifications 
frequently include genes of the CDKN2A/CDK4/RB1 and the CDKN2B/MDM2/TP53 
signaling pathways by targeting important pro-survival or pro-apoptotic genes, such as 
BCL2 (overexpressed), BCL2L11 (deleted) and FBX025 (deleted). Increased cell 
proliferation resulting from downregulation of genes (MOBKL2B, MOBKL2A and LATS1) 
involved in the Hippo-pathway has also been reported in up to 38% of MCL [92] 
 
High proliferation is one of the best predictors for inferior survival in MCL [93]. This high 
proliferation rate is largely based on several genetic aberrations that involve impairment of 
cell cycle functions, DNA damage responses and regulated cell death pathways [36]. There 
is also a signature cluster of proliferation-associated genes constructed from expression 
profiling data collected from a large number of MCLs that accurately predicted shorter 
survival for patients expressing that set of genes [68].  
 
As summarized in Table 1 from whole exome/targeted sequencing and copy-number 
studies, the pathogenesis of MCL involves several genetic alterations influencing genes 
associated with cell cycle, apoptosis, DNA repair, NOTCH signaling, BCR and NF-κB 
signaling, epigenetic modifiers, RNA and ribosomes [68, 76, 91, 94]. Since cyclin D1 
overexpression is not sufficient for oncogenic transformation of naïve B-cells into MCL, it 
was postulated from data in [90] that the t(11;14) translocation is followed by hitherto 
unknown alterations that after various latency can evoke a state referred to as in “in situ” 
MCL, now denoted ISMNC [50]. ISMNC is phenotypically and morphologically similar to 
MCL and is assumed to have fewer secondary genomic alterations; however, no further 
studies have yet been performed to confirm this. Additional acquired genetic modifications 
in a fraction of these cells would result in more malignant clones with increased genomic 
instability.  
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Impaired DNA damage response is another major factor underlying the aggressiveness of 
MCL. The ATM gene in particular, critical for promoting cell cycle arrest in response to 
double-strand breaks, is very important and has been reported deleted or mutated in 11-61% 
of MCLs (11–57% deletions, 41–61% mutations) [91]. Another important gene is TP53, 
which is also frequently mutated or deleted in MCL in 14-22% of cases [35, 64, 95] with 
17p deletions found in 32% of cases [95].  
 
Recent NGS studies were able to detect NOTCH1 and NOTCH2 mutations in a relatively 
low number of MCLs (5% and 5-14%, respectively) [64, 65], as well as genes in the NF-κB 
pathway, such as CARD11 (6%) [96]. The NF-κB pathway is also altered by mutations and 
epigenetically silencing of TNFAIP3 [97] together with BIRC3 [35, 96].  
 
Tumor cell proliferation (due to secondary genetic alterations) and specifically TP53 
mutations and TP53 overexpression are associated with disease aggressiveness in MCL 
[98]. TP53 mutational status was recently reported to identify younger MCL patients who 
were not benefited from heavy chemoimmunotherapy [99]. 
 
2.6 CURRENT STANDARDS OF CARE  
The current treatment regime for MCL is treatment with anti-CD20 antibodies and 
combination chemotherapy. Younger patients can receive high dose chemotherapy and 
autologous stem cell transplantation (ASCT). Patients who are ineligible for such intense 
treatment can be treated with targeted therapy, for instance ibrutinib [100, 101].   
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Table 1: A summary of the genetic alterations in MCL based on whole exome/targeted sequencing and copy-number 
studies. Rear=rearranged, mut=mutated, del=deletion, *found in nnMCL (table adapted Rosenquist, R., et al., Genetic 
landscape and deregulated pathways in B-cell lymphoid malignancies. J Intern Med, 2017). 
Pathway/process Gene 
Alterations in MCL (% range) (n = 
624 from seven WES/targeted 
studies and n = 219 from six copy-
number studies) 
Cell cycle CCND1 * 95% rearr, 14–34% mut 
 CCND2 3% rearr 
 RB1 25–55% del 
 LATS1 19–37% del 
 CDKN2A, CDKN2B 10–36% del 
 BCL2 3–17% gain 
 BMI1 6–12% gain 
 BRAF 0 
Apoptosis FBXO25 17–34% del 
 MYC 6–32% gain, 1% rearr 
DNA repair and integrity TP53 * 21–45% del, 14–31% mut 
 ATM 11–57% del, 41–61% mut 
 POT1 1% mut 
 TERT <1% rearr 
NOTCH signaling NOTCH1 5–14% mut 
 NOTCH2 5% mut 
BCR/NF-κB signaling BIRC3 11–57% del, 6–10% mut 
 CARD11 3–15% mut 
 TLR2 a 7% mut 
 TRAF2 7% mut 
 NFKBIE 5% mut 
 MAP3K14 2–3% mut 
 MYD88 0 
 EGR2 0 
Epigenetic modifiers KMT2D 12–23% mut 
 KMT2C 5–16% mut 
 NSD2 10–13% mut 
 SMARCA4 8% mut 
 ARID1A 0 
 SETD2 0 
RNA and ribosomes SF3B1 0 
 XPO1 0 
 RPS15 0 
Other pathways UBR5 7–18% mut 
 S1PR1 3–15% mut 
 MEF2B 3–7% mut 
 IKZF3 0 
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3 SRY-RELATED HIGH-MOBILITY-GROUP BOX (SOX) 
TRANSCRIPTION FACTORS 
3.1 BACKGROUND 
Genes that have similar functions and sharing similar physiological regulation often share 
the same short regulatory sequence, which differentiate them from other genes. 
Transcription factors are regulatory proteins that are able to specifically interact with those 
DNA sequences and induce or repress transcription of the targeted genes [102].  
 
3.2 THE SOX TRANSCRIPTION FACTORS 
The sex-determining region on chromosome Y, the SRY transcription factor, was 
discovered in the 1990s [103, 104]. In addition to identifying the gene accountable for male 
differentiation, it also paved the way for the discovery of a whole family of highly specific 
transcription factors denoted as SOX, an acronym for “SRY-related HMG box” [105]. SOX 
genes were defined as genes sharing a consensus sequence coding for the conserved 
RPMNAFMVW motif found within the High-Mobility Group (HMG) domain of all known 
SOX transcription factors [105]. Ten years after the discovery of the SRY gene, the definite 
number of SOX transcription factors amounted to 20 distinct genes, which excluded all 
previously counted orthologues [106]. Grouping based on sequence homology further 
divided them into eight distinct subgroups (A-H) [107]. The main role of the SOX genes is 
to regulate cell fate during development, tissue homeostasis and regeneration of stem and 
progenitor cells [108].  
 
The expression of SOX genes is generally tissue and developmental stage-specific, however 
the low number of SOX genes indicates that the genes are pleiotropic. Thus, the gene may 
act differently based on cell context and developmental stage. The Sox10 gene is involved 
in neural crest formation, however for early neural crest development Sox10 can be 
substituted with Sox8 (both members of the SoxE group). This stage is not affected in mice 
with a mutated Sox10 either. However, in the later differentiation stage (enteric nervous 
system), this mutation severely affects melanocyte development [109] demonstrating that 
this stage specifically requires Sox10.  
 
The HMG box domain of SOX binds to the DNA and induces a conformational change, 
forming an L-shaped structure with the DNA, which allows other previously non-adjacent 
DNA binding sites and their transcription factors to come within a close proximity to the 
SOX protein. This stabilizes and forms a transcriptional complex as outlined in Figure 3. 
 
SOX proteins regulate transcription of their target genes in three different ways [107, 110, 
111], namely via transactivation (TA) (Figure 3.1), transrepression (TR) (Figure 3.2) or 
structural stabilization (Figure 3.3). TA is performed by the C-terminal region that interacts 
with a transcriptional co-activator, which in turn binds to the TATA-binding protein (TBP) 
and TBP-associated factors (TAFs). Transrepression is also performed by the C-terminus, 
but with a transrepression domain (TR). The TR interacts with a transcriptional co-
repressor that blocks gene transcription. There are only a limited number of SOX proteins 
that solely act as structural proteins for constructing the enhanceosomes.  
 
 
  
 12 
 
  . 
  
Figure 3: Transcriptional regulation of SOX protein by binding to the DNA and induce a conformational change via 1) 
transactivation 2) transrepression or 3) transcriptional complex stabilization (modified from Lefebvre, V. et al. Int J 
Biochem Cell Biol, 2007. 39(12): p. 2195-214). 
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3.3 MOLECULAR FEATURES  
3.3.1 DNA binding 
The SOX proteins bind a short linear DNA consensus motif that can be found extensively 
throughout the genome and their binding affinity to DNA is generally lower than for other 
transcription factors (Kd of 10-7-10-9 compared with Kd of 10-9-10-11) [107]. Together, this 
complicates target specificity. However, the SOX proteins can acquire selectivity by the 
structural changes induced when the HMG domain binds to the DNA [112, 113] (discussed 
in Kondoh et al. [114] and below).  
3.3.1.1 HMG domain 
All SOX proteins include the roughly 80 amino acid residues long and highly conserved 
HMG domain of three α-helices that form a L-shaped structure [115-117] that interacts with 
the minor groove of the DNA helix via their shared consensus motif, 
(A/T)(A/T)CAA(A/T)G [118-121]. Although belonging to the same family, the HMG 
domain of the SOX proteins does not share more than 50% identity for the different groups 
[107]. However, under certain conditions they are interchangeable, for example substituting 
the HMG domain of SRY with that of SOX3 or SOX9 did not result in any loss of function 
[122]. Despite their high similarity, the different SOX proteins do not always bind to the 
same targets. By compressing the major groove while widening the minor groove the 
interaction has a major structural impact on the conformation of the DNA helix (Figure 4). 
The conformational change facilitates recruitment and association of cell-specific proteins 
and transcription factors required for the transcription otherwise positioned out of reach on 
the DNA (Figure 3) [123]. Another reason for gene specificity is the flanking region of the 
binding sites that can influence the binding affinity of different SOX proteins (SOX4, 
SOX9 and SOX10) [120, 124, 125]. Further, the context dependent interaction could also 
account for how these similar proteins may have a diverse range of functions. During eye 
development, the lens-specific enhancer element DC5 is a target for SOX2 and PAX6 that 
form a stable and specific tertiary enhancer complex. Alone each factor was able to bind to 
the enhancer, but not able to activate transcription of target genes. Instead, PAX5 and 
SOX2 together have to interact with the sequence to form a tertiary complex that positions 
the proteins in a particular spatial organization for activation [126].  
  
Figure 4: Binding of two HMG domains (displayed in opposite direction) to DNA in the minor groove 
that induce a conformational change (modified from Lefebvre, V. et al. Int J Biochem Cell Biol, 2007. 
39(12): p. 2195-214). 
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3.3.2 TAD and NLS domain  
In addition to the HMG domain, other molecular features of several of the SOX proteins are 
a C-terminal transactivation or repression domain [127-129], a nuclear localization 
sequence (NLS) situated in the HMG [130] and dimerization domains [130]. Of note, the 
transactivation domain (TAD) can also be positioned centrally. When interacting with 
different transcription factors, the TAD is a key factor for initiating and maintaining the 
protein heterodimerization state by interacting with the DNA-binding domain of the partner 
protein [112, 113]. SOX proteins are able to compete for the same target genes, as shown 
for the SOXB group where the SOXB2 proteins [131] gradually replace SOXB1 proteins. 
Since the C-terminal domain of SOXB1 is a transcriptional repressor, whereas SOXB2 is a 
transcriptional activator [132], the latter culminates transcriptional activity from a repressed 
to an activated state. Hence, the steady-state levels of highly similar SOX proteins could 
have significant biological impact on gene regulation.  
  
3.4 THE SOXC TRANSCRIPTION FACTOR GROUP 
3.4.1 Expression 
In higher order species, homology grouping identifies SOX11 (474 amino acids, human), 
together with SOX4 (441 amino acids, human) and SOX12 (315 amino acids, human), as 
members of the SOXC group of single exon genes [105, 128].  
 
The SOXC genes are highly conserved and concomitantly expressed at elevated levels 
during embryogenesis and in neuronal and mesenchymal progenitor cells [128, 133-140]. 
Postnatally, as development progress, expression of the SOXC family members is reduced 
or restricted to specific cell lineages. Expression of SOX12 has a more unconstrained 
pattern with low mRNA levels detected in most adult tissues [141]. In adult mice, Sox11 
mRNA expression is detected in neuronal tissue [142] and pancreatic islet cells [143] 
whereas Sox4 mRNA expression is restricted to B/T-cells and gonad cells [127].  
 
3.4.2 Features of the SOXC group 
The HMG domains of the SOXC group share 84% identity [128] and are known as 
transcriptional activators with a C-terminally positioned transactivation domain which 
enables all members to activate or interact with proteins in different transcriptional 
complexes. In the SOXC group, the TAD is comprised of the last 33 residues in the protein, 
but share less identity (67%). Both SOX4 and SOX11 demonstrate a very high sequence 
similarity in the TAD compared to SOX12. Nevertheless, all three members function as 
transactivators; SOX11 the most potent, SOX4 intermediate and SOX12 the weakest [128, 
144, 145]. The SOX4 and SOX12 proteins bind DNA with higher affinity on 
electrophoretic mobility shift assay (EMSA) than SOX11 [128, 146].  
 
3.4.3 Overlapping function in vivo   
Knockout experiments in mice have demonstrated that Sox4 and Sox11 have non-reciprocal 
functions during development, as Sox4−/− mice die at E14 and Sox11−/− succumbs hours 
post birth [6, 147]). In contrary, Sox12−/− mice survive embryogenesis and are born alive, 
almost indistinguishable from their wild-type littermates [145].  
 
The SoxC genes are functionally redundant up until E8.5 of embryogenesis when 
investigated in SoxC−/− (Sox4−/−Sox11−/−Sox12−/−) mice [148]. Past that stage, the study 
demonstrated how expressions of the SoxC genes were of different significance during the 
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developmental stages; the mice displayed different severity of malformation dependent on 
how the SoxC genes were deleted. From combinatorial deletion of the genes, the study 
concluded that Sox4 has a more essential role during early development by observations 
that Sox4+/−11−/− mice exhibited less malformations than Sox4−/−11+/− mice. The impact of 
Sox12 was less pronounced. Although, the SoxC−/− mice had more marked organ 
malformations in addition to increased cell death compared with the Sox4−/−Sox11−/− mice 
[149]. The observed effects are indicative for some compensatory effect by Sox12, but not 
very strong. 
 
3.4.4 SOXC expression in B-cells and cancer 
During hematopoiesis, SOX4 is necessary for pro-B cell survival [150-152]. While SOX4 
is present in lymphocytes and vital for B-cell differentiation by regulating the transition 
from CLPs to early B-cells [150], the role of SOX11 in B-cells is still not established. 
SOX11 is expressed in MCL, but has yet no defined role in hematopoiesis and is only 
rarely expressed in normal B-cells [153]. SOX12 is yet to be investigated. 
 
One fundamental function of the SOXC proteins is supporting cell survival, which is 
closely related to cancer and the relevance of the SOXC genes has gained more interest as 
more information from whole genome/exome data suggests a role in tumorigenesis. For 
example, among 40 published cancer microarray data sets, SOX4 was one of 67 genes that 
were reported as a cancer signature gene when comparing cancer tissue with healthy tissue 
[154]. Aberrant expression of SOX4 and SOX11 (the SOXC) genes is reported in several 
different tumors.  
 
In addition to maintaining survival of pro-B cells [150-152], SOX4 has been ascribed an 
oncogenic role in acute lymphoblastic leukemia (ALL) [155, 156]. However, in non B-
cells, SOX4 has also been shown to interact and stabilize TP53 by preventing Mdm2-
mediated TP53-ubiquitination, and thereby preventing tumorigenesis. This demonstrates a 
context dependent function of the SOX4 gene. Depending on cell type, the SOXC genes 
could have either a pro-apoptotic or anti-apoptotic effect. A summary of different SOX4 
expressing tumors uncover how differently the very same SOXC transcription factor acts in 
different biological contexts [157]. However, for certain cancers, such as medulloblastoma, 
high expression of SOX4 in the tumor correlated to both a favorable [158] and an 
unfavorable [159] disease progression. This can likely be due to several other factors than 
solely SOX4. 
 
3.5 THE SOX11 TRANSCRIPTION FACTOR  
Human SOX11 was discovered, cloned and mapped to chromosome 2 at position p25 
(2p25) using fluorescence in situ hybridization nearly 20 years ago [160].  
 
The structural features of SOX11 are very similar to the other SOXC genes, but there are 
certain differences, especially between the domains. The HMG domain is followed by an 
acid and proline-glutamine rich region located centrally [105] with the TAD forming an 
uninterrupted α-helical structure [146] comprised of a serine rich and a highly conserved C-
terminal region [105]. When elucidating the transcriptional regulation of SOX11, removal 
of different parts of its C-terminal region demonstrated an auto-inhibiting function as its 
ability to interact with DNA increased in EMSA [128]. This is the reason for its lower DNA 
affinity compared with SOX4 and SOX12. Posttranslational modifications could also 
influence binding capacity, but it has only been shown in vitro for SOX9 and SOXE 
proteins [107].  
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The NLS of SOX11 is responsible for nuclear import, but also reduces caspase-6 activity, 
as demonstrated after removal of the domain. Among different SOX proteins, SOX11 could 
also reduce caspase-6 activity with the highest efficacy, indicating its ability to abrogate 
cell death under certain conditions [161]. 
 
During embryogenesis, Sox11 transcripts are detected in various tissues and organs, 
including central and peripheral nervous system, branchial arches, genital tubercule, limbs, 
eyes, ears, mammary buds, nasal invagination and somites [162]. In order to investigate the 
effect of Sox11 during embryogenesis, different knockout models have been established 
(Sox11−/− [147] and SoxC−/− [148]). Postnatally, the Sox11−/− mice succumbed from 
cyanosis as a consequence of severe cardiac defects or pulmonary insufficiency due to 
significant hypoplasia of the lungs. The newly born mice had 23% lower birth weight. 
Other recurrent defects involved absence of spleen, underdeveloped lung, stomach and 
pancreas in addition to skeletal and craniofacial malformations. The nervous system did not 
exhibit as profound malformations as other tissues. The neural cells did not exhibit a 
significant reduction in proliferation following Sox11 inactivation. A possible theory could 
be that the highly homologous Sox4 is found co-expressed in the nervous system and could 
partly compensate for the loss of Sox11 [148]. 
 
These experiments demonstrate the importance of Sox11 in regulating cell survival during 
organ growth and neurogenesis in vivo [139, 142, 145, 163]. After establishing its role as a 
master regulator during development in mice, de novo mutation in the human orthologue 
have now been found to be that is responsible for certain congenital/developmental 
diseases, such as Coffin-Siris syndrome [164]. SOX11 is also directly involved in a unique 
case with 2p25 duplication and CHARGE syndrome [165].  
 
While SOX11 is necessary for embryogenesis, postnatal expression is restricted in most 
tissues [133, 148, 166]. In non-malignant tissue, Tubb3 [128], important for axon guidance 
[167] and Tead2 [148], important for the Hippo signaling pathway [168] are so far the only 
known and validated genes that are directly targeted by SOX11. The formation of 
transcriptional complex to induce gene activity is dependent on binding partner. However, 
there are only few known proteins identified and validated as binding partners to SOX11: 
BRN1 (yeast-two-hybrid screening) [169] and NGN1 and BRN2 (co-immunoprecipitation) 
[170]. 
 
The cellular background and context are critical for the function of the SOX transcription 
factors. SOX11 can, in addition to SOX2 and SOX10, under correct binding conditions 
synergistically interact and cooperate with different POU domain proteins to enhance 
transcriptional activity: SOX2 with Oct-3/4 [171], SOX10 with Tst-1/Oct6/SCIP [172] and 
SOX11 with BRN1 [172]. Unsuitable binding partners to SOX11 were unable to activate 
transcription, or even lead to a reduced response as they interacted [172]. Transcriptional 
activity of SOX11 could theoretically also be influenced by the concentration and 
availability of the other SOXC members. Due to its higher DNA affinity over SOX11, but 
lower TAD activation capacity [128], the most substantial effect would be with SOX12. 
Hence, having a higher DNA binding affinity, SOX12 could potentially interfere with the 
genes SOX11 normally target. 
 
Neural cells are one of the most studied cell types with regard to Sox11 and overexpression 
of Sox11 has been reported to have an inductive effect on pan-neural markers and the neural 
cytoskeleton [133, 142]. However, not all neural cells are the same. Overexpressing of 
Sox11 in two different types of retinal ganglion cells (RGCs), α-RGCs and non-α-RGCs, 
resulted in two contrasting outcomes; cell death and axon regeneration, respectively [134, 
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173]. Moreover, adult neural precursor cells do not differentiate in the absence of Sox11; in 
contrast, gain of Sox11 initiates adult neurogenesis in immature neurons [142, 174] as well 
as regeneration of damaged peripheral nerves [175] and ensuring sensory neuron outgrow 
[176]. 
 
4 THE ROLE OF SOX11 IN CANCER 
4.1 EXPRESSION PATTERN 
Nuclear staining of SOX11 can be detected in MCL [25, 26], but it is also expressed in 
subsets of medulloblastoma [158], malignant glioma [177], ovarian cancer [178] and breast 
cancer [179]. Regarding lymphoproliferative diseases other than MCL, certain BL, subsets 
of precursor B/T-cell lymphoblastic neoplasia, especially B-ALL with the TEL-AML1 
fusion or E2A rearrangement, and hairy cell leukemia (HCL) also express SOX11 (protein 
or mRNA) [180, 181]. However, transcript levels of SOX11 are otherwise very low in other 
lymphoproliferative diseases, including most ALL and BL, CLL, follicular lymphoma (FL), 
diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma 
(PMBL) [181]. SOX11 expression was also shown to be low in nnMCL, a subset suggested 
to be correlated with indolent disease [33, 45, 181, 182].  
 
In conclusion, high expression of SOX11 has been reported in different B-cell lymphoid 
malignancies and solid tumors with the expression associated with differential clinical 
outcome [54, 153, 183-186], again illustrating how context dependent the SOX11 gene is. 
 
4.2 FUNCTIONAL ROLE IN NON-MCL DERIVED TUMORS 
The role of SOX11 in cancer varies, but the capacity to proliferate and survive appears to 
be influenced in several cancers expressing SOX11.  
 
As an example, SOX11 is upregulated in certain gliomas (however, only very few cases in 
the study) [177]. Xenotransplanted mice with Sox11 expressing glioma cell lines had longer 
survival (60 days compared to 45 days for the non-Sox11 expressing cell lines) [183]. Thus, 
in this context Sox11 has a tumor suppressive effect by differentiating the cells, compared 
to the proposed oncogenic effect of SOX11 in the human gliomas. Moreover, in certain 
ovarian cancer, high SOX11 expression has shown to correlate with a longer recurrence-
free survival [178]. Therefore, its functional role is not clear in most cancers. For MCL, its 
functional role is even more ambiguous with several well-conducted studies reporting 
conflicting data [187, 188].   
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5 SOX11 IN MCL 
5.1 BACKGROUND 
MCL is predominantly diagnosed by morphology and (11;14)(q13;q32), or cyclin D1 
overexpression. However, after recognizing SOX11 to be expressed in over 90% of all 
MCLs [25, 26, 45, 180, 189, 190], the transcription factor has gained considerable interest 
as a potential biomarker and potential master regulator in MCL. The SOX11 protein is not 
expressed in the vast majority of lymphomas or mature B-cells and its expression is 
independent of cyclin D1 status. Given the aggressive disease progression and recent 
advancements in treatment regimens tailored for MCL, it is important to correctly diagnose 
the disease. Taken together, SOX11 can facilitate differential diagnosis and identifying 
MCL, which is especially useful for certain morphologically and phenotypical similar 
lymphomas, such as CLL and MZL [25, 26, 190]. 
5.2 SOX11 EXPRESSION IN MCL, A DOUBLE-EDGED SWORD? 
Within the field of MCL, the role of SOX11 as a diagnostic marker is undisputed; however, 
its role as a prognostic marker is not. The reliability of SOX11 as a diagnostic marker has 
been verified in numerous cohorts (to mention some of the studies) [25, 33, 45, 54, 153, 
180, 185, 190, 191]. However, not all of these studies are coherent with regard to clinical 
outcome, definition of indolent disease, percentage of cases with nodal presentation and 
SOX11 expression. In some studies, SOX11- MCLs had longer survival [33, 45, 53, 182], 
whereas in other studies SOX11- MCLs had shorter survival [26, 54, 153, 185, 191, 192]. 
The reasons for the inconsistency are still not fully understood. Nevertheless, there are 
certain parameters to consider when interpreting these conflicting results: 
 
1) Detection specificity (antibody/primers used) 
2) Stratification (from where are the patients collected) 
a. Clinical behaviour 
b. Treatment  
c. Geographical area 
 
The sensitivity and specificity of the different SOX11 antibodies may differ [153, 193, 
194]. Clinical behavior is also important as there have been suggested to exist several 
different entities of MCL [50], particularly the classical MCL situated in the lymph node 
(low grade of SHM, high degree of genetic alterations and aggressive behavior) and 
leukemic non-nodal MCL (high grade of SHM, low degree of genetic alterations and less 
aggressive behavior). 
 
In the studies of Fernandez et al. [45] and Navarro et al. [33], the SOX11- cases used were 
characterized as nnMCL, and as previously described, this entity is much more indolent 
than the classical type of MCL. In Lord et al. [153], samples were largely population based 
and not a coherently treated collection.  Both the study by Nygren et al. [54] and Nordström 
et al. [185] included several SOX11- cases with strong TP53-positivity, a factor previously 
shown to be associated with shorter overall survival (OS). The SOX11- cases could be 
derived from indolent nnMCLs that later acquire 17p/TP53 mutations, however Nordström 
et al. [185] emphasizes that no indolent MCLs were included in their study. Meggendorfer 
et al. [192] reported that in MCLs (t(11;14)-positive and t(11;14)-negative) SOX11+ 
patients showed a more indolent course compared with SOX11- MCLs. Further, 
SOX11+/t(11;14)− cases had a more adverse prognosis than SOX11+/t(11;14)+ MCL 
patients. 
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5.2.1 Diagnosing MCL  
Although MCL can be diagnosed by morphology, phenotype and t(11;14)(q13;32) or cyclin 
D overexpression,  SOX11 protein is now routinely used in the diagnostic work-up. 
Detection of SOX11 is primarily performed by IHC/ICC, but there is now a validated 
protocol for detecting expression using flow cytometry [195]. This is practical for cytology 
and blood samples. Detection of SOX11 mRNA expression by quantitative polymerase 
chain reaction (qPCR) can also be used in MCL and has high concordance to SOX11 
detection by immunohistochemistry (IHC) [153]. Additionally, SOX11 mRNA expression 
correlates with the t(11;14)(q13;32) translocation in patient samples [192, 196]. 
5.3 REGULATION  
As previously mentioned, MCL is characterized by a high degree of chromosomal 
instability and genetic aberrations. However, several studies with large numbers of MCLs 
investigated have not detected any genetic alterations in or near 2p25 where SOX11 gene is 
located [59, 92].  
 
Since no apparent genetic reason is behind the observed overexpression of SOX11 in MCL, 
it is expected to be epigenetically regulated. Interestingly, compared to the majority of BL, 
CLL, FL, DLBCL, breast cancer, ovarian cancer, lung cancer and brain cancer cases that all 
are negative for SOX11, the SOX11 promotor is not heavily methylated in MCL (cell lines 
and primary samples) [181, 197-200]. The vast majority of investigated B-cells have 
hypomethylated promotor region, but are still epigenetically silenced compared to MCL. 
 
Further verification that the promotor region of SOX11 is not methylated was performed by 
5-azacytidine (5-AZA), an inhibitor of DNA methyltransferase. No increased expression 
was detected as would have been the case for a heavily methylated promotor region. Hence, 
SOX11 expression is not governed by promotor methylation in MCL. Expression is instead 
regulated by histone modification via activating histone mark [181, 200], as demonstrated 
for two SOX11- cell lines (one hypomethylated MCL cell line and one hypermethylated BL 
cell line). Inhibiting histone deacetylases significantly elevated SOX11 expression for both 
cell lines, showing how the treatment re-activated the SOX11 gene.  
 
Lastly, circularized chromosome conformation capture (4C)-Seq data recently identified a 
distant enhancer element binding to the SOX11 locus in 3D. This region, positioned 650 kb 
downstream of SOX11 differed in methylation status for SOX11+ and SOX11- MCL 
(Figure 5). Bisulfite sequencing showed it to be de novo demethylated in SOX11+ 
compared with SOX11- MCLs and cell lines [21].  
 
In conclusion, SOX11 can potentially be regulated by promotor methylation in other 
lymphoma and certain solid cancer types as have been shown in the above studies [199]. 
However, in the particular context of MCL, the SOX11 is regulated by histone modification 
[181] and potentially also a distant enhancer element [21]. Interestingly, in the 
hypermethylated BL cell line Raji, SOX11 can be re-activated by both the de-methylation 
agent 5-AZA and the histone deacetylase inhibitor SAHA.  
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5.4 SOX11 TRANSCRIPTIONAL TARGETS IN MCL 
So far, three different studies have conducted chromatin immunoprecipitation (ChIP) 
experiments to discover transcriptional targets of SOX11. The initial study was based on 
genes identified after SOX11-specific small interfering RNA (siRNA) knockdown followed 
by gene expression profiling after 20 hours in the MCL cell line Granta519. The 26 
differentially expressed genes were then validated in data sets from primary MCLs, out of 
which DBN1, SETMAR and HIG2 significantly correlated to SOX11. They were next 
confirmed to bind by ChIP-qPCR [201]. A similar approach was performed for Granta519, 
Z138 and JeKo-1, but with longer time of exposure to SOX11-specific siRNA (48 hours) 
and RNA-seq. The three cell lines encompassed 2799 differentially expressed genes. ChIP-
Seq in Granta519 identified 1912 unique SOX11-bound genes out of which SMAD3, 
TGFBR1, WNT4, NLK and PRKACA were validated by ChIP-qPCR [191]. In a third study, 
2790 differentially expressed genes were found when gene expression profiling was 
performed on Z138 cells transduced with SOX11-specific short hairpin RNA (shRNA) for 
stable knockdown. ChIP-Chip in Z138 identified 1133 (1132) genes bound by SOX11. 
When overlaying GEP and ChIP-ChiP data, 147 genes were bound by SOX11. From them 
PAX5, MSI2, HSPD1, SUV39H2, and SEPT2 were validated by ChIP-qPCR [188].  
 
When the authors in the studies cited above [188, 191] performed GO-term and KEGG 
Pathway analysis on the genes identified in each separate SOX11-binding study, there were 
two main findings. Kuo et al. [191] found pathways related to cancer (WNT and TGF-beta 
pathway genes ranked highest) [191], whereas Vegliante et al. [188] found hematopoiesis 
and hematological system development to be the key pathways highly enriched. 
Overlapping pathways for these two studies were proliferation and tissue 
invasion/hematological system development and function. However, the actual intersect 
between the two studies only consists of 96 genes (Figure 6) after I compared the two data 
sets. A GO-term analysis of the overlapping genes only shows enrichment of a few 
processes (negative regulation of transcription and brain and developmental processes).    
  
Figure 5: Concept of 4C and distant SOX11 enhancers (modified from Queiros, A. 
C. et al Cancer Cell, 2016. 30(5): p. 806-821).  
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5.5 FUNCTIONAL ROLE OF SOX11 IN MCL  
In spite of recent breakthroughs in MCL, the molecular mechanism of SOX11 in MCL and 
its potential binding partners in the transcriptional complex is still not fully understood. 
 
Transient siRNA-knockdown of SOX11 in Granta519 altered a group of genes involved in 
cell shape and motility, but there were no detectible changes in cell morphology [201] or 
increased proliferation [197]. Genes involved in WNT/TGF-β pathways are also direct 
targets of SOX11 (ChIP-Seq) and differentially expressed after transient siRNA-
knockdown of SOX11 in Granta519 and other MCL cell lines [191]. Dysregulated WNT 
signaling can lead to malignant transformation of cells and WNT-signaling is often found to 
be upregulated in MCL [202].  However, when Kuo et al. [191] overexpressed SOX11 in 
the same cell lines, members of the WNT pathway were functionally repressed. Moreover, 
cells showed a significantly reduced proliferation rate with an increased proportion of cells 
in the G2/M-phase. This is in agreement with a previous report where overexpression 
reduced proliferation rate in Granta519 and Z138, and upregulation of TGF-β, BRCA1 and 
SMAD2/3 in Granta519 [197].  
 
In another study, the functional roles of SOX11 were interrogated after stable knockdown 
of SOX11 by shRNA in Z138 cells. Their gene signature abruptly shifted to that of one 
more similar to the plasma cell differentiation program when compared to the control cells, 
which represented that of the mature B-cell program. Moreover, downregulation of SOX11 
additionally reduced cell proliferation and the size of engrafted tumors [188], contrary to 
results from when overexpressing SOX11 in the same cell line [191]. Downregulation of 
SOX11 protein expression leads to decreased PAX5 activation and upregulated BLIMP1. 
PAX5 is needed to establish the B-cell identity [203], but it also binds and repress the 
promotor of the BLIMP1 gene, leading to block of plasma cell differentiation [204]. Hence, 
low SOX11 could promote differentiation from a mature B-cell into a more plasmacytic 
differentiated subtype [188]. SOX11 has also been speculated to prevent naïve B-cells 
carrying the t(11;14)(q13;q32) from leaving the mantle zone since it is able to bind to the 
promotor of BCL6 with a repressive effect as shown by luciferase assays [205].  
 
 
Figure 6: Venn-diagram showing the overlap of significantly (FDR<0.05) target genes 
reported in the above mentioned studies [188 and 191]. Data plotted in R. 
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Therefore, overexpression would repress transcription of BCL6, which stops the cells from 
entering the GC and preventing them from going through SHM and further differentiation 
steps. Investigations in the same SOX11 shRNA-knockdown model system further showed 
that SOX11 can induce angiogenesis by transcriptionally activating PDGFA [206]. 
Reported in Conrotto et al. [187], upon SOX11 downregulation, ATX is one of the most 
highly upregulated genes. The gene is involved in producing a lysophosphatidic acid (LPA) 
responsible for stimulating angiogenesis and often found in tumors [207], so angiogenesis 
could potentially also be negatively affected by SOX11 in MCL. However, there are no in 
vitro or in vivo studies supporting this. Further, cell counting and 3H‐Thymidine 
incorporation demonstrated an increased proliferation rate upon downregulation of SOX11 
protein, as well as more cells in the S-phase. Engraftment of these SOX11 knockdown cells 
into mice also led to shorter survival compared to mice engrafted with corresponding 
control cells. 
 
In summary, SOX11 directly binds and influence genes critical for cell shape and motility, 
proliferation, cell cycle, apoptosis, B-cell differentiation, angiogenesis and tumor 
microenvironment. The proposed mechanistic model on MCL pathogenesis could 
theoretically partly be explained by how SOX11 regulates PAX5 and BLIMP1, which are 
important for GC-formation and B-cell differentiation. 
 
5.5.1 Discrepancies between oncogenic effects of SOX11 in a MCL model  
Based on data from Vegliante et al. [188], SOX11 has been proposed to function as an 
oncogene in MCL [208]. However, studies regarding the influence of SOX11 on cell 
proliferation in MCL cell lines have yielded conflicting results [187, 188, 191, 197]. 
Overexpression of SOX11 in Z138 and Granta519 resulted in decreased proliferation [191, 
197], whereas transient knockdown increased proliferation [197].  
 
Notably, two well-conducted and experimentally very similar studies reported contrasting 
results.  One study reported that stable knockdown of SOX11 (using shRNA in Z138) 
resulted in decreased proliferation [188], whereas the other study reported increased 
proliferation [187]. Both studies also investigated tumor growth in xenografts with the same 
conflicting results. However, different mice strains were used (NOD-SCID and CB17-
SCID) and different injection methods were used (intravenously in the tail vein and 
subcutaneously into the lower dorsum). This could influence the tumor engraftment, but 
requires further validation of the in vitro data.  
 
Regarding the in vitro data, despite that both studies verified downregulation on 
transcriptional and protein level, only 10 genes overlapped when I investigated the intersect 
of the reported genes for the two studies using the genes that were reported as significantly 
differentiated (Figure 7). The small overlap indicates a significant difference in SOX11 
gene regulation for the two cell lines that should not be due to the different expression 
platforms used. Normalization was performed with the Robust Multichip Analysis (RMA) 
algorithm and adjusted for false discovery rate (FDR). Expression is to some extent  
analyzed differently, the old HG-U133 Plus 2 (Vegliante et al. [188]) implements a Perfect 
Match (PM) and Mismatch Probe (MM) to  remove noise, whereas the Human Gene 1.0 ST 
Array only implements PM (Conrotto et al. [187]). The PM and MM ratio is used to 
determine non-specific binding by inserting a mismatch in the central position of the probe 
[209].  
 
The relevance of cellular context and expression levels have previously been discussed for 
several SOX proteins. Here, the cellular context is highly similar (equal cell line, Z138) if 
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no genetic drift has occurred that would explain their dissimilar response to reduced levels 
of SOX11 protein in the cell. Z138 has high levels of SOX11 protein, but the cell line was 
derived from the more rare cases within the MCL entity (a MCL in leukemic phase that 
also has extremely prominent splenomegaly) [210]. Reduced levels of SOX11 protein were 
clearly observed in both studies, but how pronounced the reduction was for the studies 
might not be identical. Highly speculative, potentially the SOX11 expression levels have a 
larger influence than initially considered.  
 
Hence, additional studies are needed in order to clarify the molecular function of SOX11 in 
MCL. The clinical relevance of SOX11 levels was addressed in Paper III by investigating 
how SOX11 mRNA expression correlated to different clinical parameters. 
 
 
Figure 7: The intersect of differentially expressed genes (FDR<0.05) reported for the above mentioned studies. Only 10 
genes are found to be overlapping for the two studies [187 and 188]. Data plotted in R. 
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6 COMMENTS ON THE METHOLOGY  
6.1 CELL LINES AND PRIMARY CELLS 
Cell lines predominantly used in this thesis include the MCL cell lines (TP53-status 
indicated with wt or m [145, 211, 212]): Granta519(wt), JVM2(wt) and JeKo1(m) were 
obtained from DSMZ; Z138(wt) and Mino(m) were obtained from ATCC; Rec1(wt) was a 
kind gift from Dr. Christian Bastard, Ronan, France. Additionally, one murine pro-B cell 
line, Ba/F3 [213] was  used.  
 
Primary lymphoma cells were isolated from tumor biopsies, mainly lymph nodes and 
tonsils, followed by filtration to remove cell debris and clumps and washed in PBS. 
Lymphocytes derived from bone marrow and blood were isolated by Ficoll separation. 
Cells were viability frozen in 10% DMSO, 40% FBS and 50% RPMI-GlutaMax medium at 
-150°C. 
 
For all experiments, cell lines were cultured in RPMI 1640 GlutaMAX™ (Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum (FBS), 50 µg/ml gentamicin 
(Invitrogen) at 37°C and 5% CO2. For Ba/F3, 5% of IL-3 supernatant from transfected X63 
cells previously described by Karasuyama et al [214] was also added. For ecotropic 
pseudotyped virus production, Phoenix cells (293T) were used. Cells were maintained in 
complete DMEM medium and in OptiMEM medium during transfections. 
 
The different MCL cell lines are all positive for cyclin D1, but they differ in morphology 
and proliferation rate. The level of SOX11 overexpression also varies between the cell 
lines. Importantly, SOX11 expression is not detected in JVM2, which provides a good 
negative control when validating experiments based on different detection methods (e.g. 
western blot or flow cytometry).  
6.2 INDUCIBLE EXPRESSION SYSTEM 
The complete coding sequence encompassing specific cloning sites with a Kozak sequence 
were generated from purified plasmids containing the mouse Sox11 gene (Q7M6Y2 
plasmid kindly provided by Dr. Veronique Lefebvre, Dept. of Cell Biology, Cleveland 
clinic, Cleveland, OH, USA). Also used, but not shown in this thesis, were human full-
length CDS or TAD truncated Sox11 and SOX11, in addition to Myc, Bmi1 and Bcl2l1.  
 
To investigate the influence of the Sox11 gene in early B-cells without strong oncogenic 
drivers, the non-malignant Sox11-negative Ba/F3 cell line was used. Previously, Ba/F3 cells 
have been used when attempting to establish a blastoid MCL murine model with cyclin D1 
overexpression [215]. However, as a MCL model, it does not recapitulate the phenotype 
and all the secondary genetic alterations. Instead the cell line was used to investigate the 
impact of Sox11 on early B-cells with regards to global gene expression, viability, 
differentiation and tumorigenic capacity. In order to investigate the effect of SOX11 protein 
expression a doxycycline-inducible murine retroviral vector with an internal ribosomal 
entry site (IRES) was employed to transduce primary murine B-cells and the Ba/F3 cell 
line. The IRES enables co-expression of Sox11 and enhanced GFP [216] in one vector.  
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This allows expression to be indirectly monitored by flow cytometry. Using an inducible 
expression system allows for cells from the same culture to be studied in the experiments 
(they come from the same culture before the experiment and not cultured separately as the 
case for constitutive overexpression/downregulation models).  
6.3 GENE EXPRESSION  
In this thesis, two different methods were employed to investigate gene expression (as 
measured by mRNA transcript levels), quantitative PCR and DNA microarray.  
6.3.1 Quantitative PCR  
qPCR was conducted using SYBR green, a fluorescent dye which intercalates with each 
new copy of double-stranded DNA (dsDNA) [217] produced from the PCR reaction. As 
SYBR green binds all dsDNA, the increase in fluorescence is proportional to the amount of 
synthesized DNA. The main advantage using a fluorescent dye that can intercalate with any 
dsDNA is that no specific probe binding to the target is required, instead well-designed 
PCR primers are used, which often is faster and less costly. However, emphasis is on well-
designed primers and characterized PCR product as any dsDNA will be detected. We used 
SYBR green to analyze gene expression in Paper I-IV by the ΔΔCt method by having β-
actin as reference and tonsil B-cells as control to calculate the ΔΔCt value and to determine 
the relative fold increase (RFI). Drawbacks with qPCR in general are sample preparation, 
template amount, primer specificity and non-proportional fluorescence to amount of 
produced PCR product since longer fragments risk binding more SYBR green. Therefore, it 
is important normalize expression using genes, known as housekeeping genes, with stable 
expression over different samples and treatment groups. We used ACTB, which has shown 
to be a stable housekeeping gene [218] when investigating all primary MCLs (Paper I- III) 
and for our McrBC-based methylation assay (Paper I).  
 
All SOX11/Sox11 gene expression experiments were conducted in biological and technical 
triplicates for Paper I-IV and evaluated using the SOX11- cell lines JVM2 and Ba/F3. 
Primary SOX11- MCLs by IHC were also used for this.  
 
When analyzing over 100 primary samples for quantitative levels of SOX11 expression, 
qPCR is a relatively fast and robust method. It gives a better resolution of quantification 
than relying on IHC stained tissue, which is more of a binary method (even though the 
methods of detection has improved with computer based quantification). The qPCR method 
allows quantitative analysis of a specific marker, which can be correlated to clinical 
parameters (Paper III). The major drawback of performing this type of study using qPCR 
is the inability to explore expression of a large set of genes at the same time for the same 
sample. The alternatives are DNA microarray and DNA/RNA-sequencing (the latter more 
expensive, but also more informative). They provide expression levels for all genes in 
addition to the gene of interest, which is a major advantage when knowing how complex 
MCL is. However, the specific purpose was to investigate how SOX11 mRNA levels 
correlated to clinical parameters, making qPCR a reasonable method for this type of study.  
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6.3.2 DNA microarray 
For Paper IV, the Affymetrix GeneChip™ Mouse Gene 1.0 ST Array for complete 
expression profile of mRNA and long intergenic non-coding RNA transcripts (lincRNA) 
was used. Here, the array was used to assess changes in global gene expression to Sox11 
expression in a non-malignant B-cell that significantly changed the morphology of the cells. 
The Affymetrix concept is based on in situ-synthesized high-density oligonucleotide probe 
DNA microarrays where short oligonucleotides at specific coordinates are synthesized on 
the array. Multiple probes per gene are used as well as perfect match probes (100% 
sequence identity to the gene) with two sets of negative control probes: “antigenomic 
background probes” (sequences with no match in genome) and “genomic background 
probes” (sequences unlikely to be transcribed). RNA extracted from Sox11 and SOX11 
transduced Ba/F3 cells, normal Ba/F3 cells, all cultured with and without doxycycline, were 
converted to biotin labelled complementary RNA (cRNA) and hybridized to the array.  
 
Microarrays provide a straightforward comparison and normalization between samples 
compared to RNA-sequencing, which could have certain algorithmic and logistical 
challenges in relation to data analysis and data storage. However, RNA-sequencing also 
provides a way to find novel transcripts, allele-specific expression and splice junctions 
since it does not rely on any genome annotation for probe design [219]. Thus, it could be 
feasible as an initial comparison to first investigate differences by microarray and then 
perform a more comprehensive study by sequencing. We were interested in the particular 
differences in gene expression levels between ON and OFF conditions to find genes 
responsible for the observed morphological effect. What changed when turning on Sox11 to 
that extent that the cells started to form aggregates and stopped dividing? The downside is 
difficulties to detect low abundant gene transcripts. The relationship between probe 
intensity and transcript levels in relation to its affinity during hybridization is also a 
concern. Moreover, the expression is only relative and not absolute. Although certain 
drawbacks, implementing the microarray approach in this context is feasible as a first step 
since we were not primarily searching for novel transcripts. Instead we implemented it to 
recognize significantly differentially expressed genes. In the future, specific patient samples 
with those genes could then potentially be de novo sequenced for a deeper understanding. 
In turn, the collected result from those experiments could be validated by microarrays to 
reduce costs. One approach to reduce cost would be to use them not interchangeable, but 
for well-defined purposes. In particular, microarrays could be used to find interesting cases 
among a large sample collection. The interesting cases could then be investigated by 
RNA/DNA-Seq and finally validated by microarray in large cohorts.   
6.4 EPIGENETICS  
In Paper II, three different approaches were used to study whether or not SOX11 
expression is regulated via promotor methylation. As suggested when choosing a suitable 
method for DNA methylation analysis for a known gene [220], the following methods were 
used. The use of two experimentally different concepts also supports the results. The 
shortcoming of these methods are that neither restriction or bisulfite conversion are able to 
discriminate between 5-methylcytosine and 5-hydroxymethylcytosine DNA [221] (info 
below).  
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6.4.1 McrBC-based methylation assay 
DNA was treated with McrBC endonuclease, which digest DNA at methylation sites (5-
methylcytosine, 5-hydroxymethylcytosine or N4-methylcytosine) [222]. Cleaved DNA 
indicates higher degree of methylation, detected by difference in ΔCt between McrBC-
treated and control. Hence, methylated CpGs had higher ΔCt value for their respective PCR 
fragment.  
6.4.2 Bisulfite treatment and pyrosequencing analysis 
Sodium bisulfite treatment of DNA deaminates unmodified cytosines to uracil while 
leaving 5-methylcytosine or 5-hydroxymethylcytosine DNA. In the subsequent PCR 
amplification reaction of the selected promotor fragment, the uracils are amplified as 
thymines whereas modified cytosines are resistant and get amplified as cytosines [223].  
Next is detection by pyrosequencing. Based on the principle of sequencing by synthesis, the 
nucleotide sequence of the fragments are detected (for an in-depth description [224]). The 
ratio based on signal intensity for incorporated dATP and dGTP determines to what extent 
the fragment is methylated. Given that pyrosequencing is very sensitive and can detect 
subtle differences in methylation, tumor samples are highly suitable as they often are not 
very homogenous [220]. 
6.5 PROTEIN DETECTION  
Several different methods are available to detect and identify protein. In this thesis western 
blot (WB), immunohistochemistry (IHC), immunocytochemistry (ICC) and flow cytometry 
were used.  
6.5.1 Western Blot 
WB was used in Paper I, II and IV. The technique is based on separating proteins by size 
that is proportional to their charge and detecting those using antibodies in a later stage. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), where denatured 
and negatively charged proteins were separated according to size as smaller proteins 
migrate faster through the gel than larger proteins (towards a positively charged electrode), 
was used to separate proteins. The proteins were transferred onto a polyvinylidene fluoride 
(PVDF) membrane, blocked and stained with a primary antibody, followed by a secondary 
antibody. Enhanced chemiluminescence (ECL) solution was used for detection of the 
specific protein. Two different SOX11 antibodies, one polyclonal (pAb) (Paper I, II and 
IV) and one monoclonal (mAb) (Paper II and III) were used in this thesis. Recognizing 
only one epitope, greater specificity is achieved with a monoclonal antibody compared with 
a polyclonal antibody that also can suffer from batch-to-batch variance. Also, working with 
the highly similar SOXC proteins, cross-reactive could be an issue (however, recognizing 
multiple epitopes could be beneficial for co-immunoprecipitation where the epitope could 
be masked). The same batch of pAbs were used for experiments and specificity validated 
by knockdown of SOX11 by siRNA and the use of JVM2 as negative control. The 
downside of using chemiluminescent detection for WB is the risk of signal saturation and it 
is not the best quantitative method, although very sensitive. Alternative, fluorescently 
labelled secondary antibodies can be used for detection. It allows for multiplexing and a 
better quantitative detection, since the fluorescent signal is directly proportional to the 
amount of protein. However, WB is still best viewed as a semi-quantitative method to 
detected target protein. Lastly, WB further requires a reference protein that is well selected 
and do not change upon treatment/manipulation (similar to qPCR).  
6.5.2 Immunohistochemistry (IHC) and Immunocytochemistry (ICC) 
IHC and ICC are important to validate SOX11 expression and its nuclear localization in 
MCL cells in patient tissue or primary cell samples. IHC staining for SOX11 was 
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performed on whole sections of paraffin-embedded patient biopsies by a Bond Max robot 
(detailed description in [54]). We evaluated the pAb and mAb SOX11 antibodies in Paper 
III, 7 cases previously negative for SOX11 with the pAb became positive with the mAb. 
This difference could be due to higher specificity of the mAb, which can detect lower 
amount of protein in MCL cases. As WB, IHC should also be considered as a semi-
quantitative method to detected target protein. Staining for fluorescent microscopy was 
used to verify nuclear specify of the MRQ-58 SOX11 mAb. The staining procedures 
require optimization (fixation, permeabilization etc.) and good controls, especially negative 
controls (both for the primary antibody and the target tissue/cell) since non-specific staining 
can be a problem.  
6.5.3 Flow cytometry   
Cells are injected into the flow cytometer where they are aligned into single cells in a 
narrow flow-channel after which they are exposed to a laser and excited light is captured by 
detectors. When quantifying protein expression, intracellular flow cytometry provides 
certain advantages over WB and IHC. In addition to simplicity and reduced time, the main 
advantage is the possibility to employ more markers for phenotyping of cells expressing 
SOX11. In Paper II, we demonstrate that protein expression measured by flow cytometry 
correlates to that of WB, but it gives a higher resolution as fluorescent intensity was used 
compared to chemiluminescence.  Drawbacks are permeabilization methods, which require 
optimization and might not always work for fragile cells. This is something we noticed in 
Paper II; Triton X-100 gave higher SOX11 intensities, but did not preserve the forward 
scatter/side scatter (FSC/SSC) distribution to the same extent as saponin (the other solution 
we investigated). The negative control cell line, JVM2 was also significantly affected by 
this permeabilization and could therefore not be used. Knockdown by siRNA or shRNA to 
validate SOX11 serves as a good substitute. Saponin interacts with membrane cholesterol 
and removes it, resulting in holes in the membrane while Triton X-100 is non-selective and 
thus potentially tougher on the cell membrane [225]. 
6.6 VIABILITY AND PROLIFERATION ASSAYS  
Cell viability measurements have been performed in Paper I-IV. They all have their pros 
and cons, and this is the reason to use all of them in Paper IV when studying viability and 
proliferation.  
6.6.1 Trypan blue exclusion 
Trypan blue exclusion is the most common method for counting living cells and it is based 
on the concept of an intact cell membrane exclude the trypan dye. Hence, trypan blue 
measure membrane integrity. For the cell lines used in Paper I-IV, trypan blue worked 
reliably (without an automated cell counter, the observer subjectively determines if the cell 
is blue or not) to observe stained and unstained cells. However, primary cells rapidly turned 
blue despite being alive. It could be due to temporary weaknesses of the membrane 
integrity, either as consequence of damage during the isolation procedure or because they 
are more permeable by nature. So, for primary cells especially, multiple rounds of counting 
were performed for every experiment.  
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6.6.2 XTT 
XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) is an 
easy and fast method for assessing cell viability based on mitochondrial activity of viable 
cells (used for Paper IV). It does not require any radioactive labelling. The water soluble 
yellow colored tetrazolium salt, XTT, is cleaved by mitochondrial dehydrogenases and 
forms an orange formazan dye. Only metabolically active cells are able to perform this 
conversion. The dye is then measured by spectrophotometry, which directly correlates to 
total metabolic activity and indirectly to the sum of viable cells. The disadvantage of XTT 
is that the assay measures metabolic activity and this is not always the same as viability or 
proliferation. Cells could be alive, but have a reduced metabolic activity as shown for 
several cell types. Contrarily, cells could be equipped with very active metabolic enzymes 
and co-factors. Therefore, using the correct control is of importance and understanding the 
limitations of what conclusions that can be drawn from the results. 
6.6.3 3H-Thymidine incorporation 
3H-Thymidine incorporation was used for Paper IV when investigating proliferation. It is 
one of the more reliable methods to measure proliferation since radiolabeled 3H-Thymidine 
is incorporated into newly synthesized DNA strands, hence it directly corresponds to DNA 
synthesis. Incorporation is also an advantage compared to the XTT assay that relies on 
metabolic activity, which can be disturbed by different compounds. For detection, labelled 
DNA is recovered from the cells and radioactivity measured by a scintillation beta-counter. 
6.7 BIOINFORMATICS 
Bioinformatics and statistical analysis were performed in R and based on the Bioconductor 
platform and its packages. 
 
source("https://bioconductor.org/biocLite.R") 
biocLite("biomaRt") 
 
For microarray analysis performed, CEL files were imported in to the transcriptome 
analysis console program TAC (v.1.4.1) and normalized by RMA. Pair-wise comparisons 
between expression values for different samples were interrogated for differential gene 
expression by two-tailed unpaired Student's t-test and the results were adjusted for multiple 
testing by false discovery rate (FDR). Significantly differentially expressed genes were 
genes with a FDR q-value ≤ 0.05. 
 
For comparison between Ba/F3 data and other human expression studies orthology 
conversion of mouse gene symbols to official human gene symbols was performed via the 
biomaRt bioconductor package (biomaRt v2.30.0, Bioconductor v3.4, R v3.3.2) with the 
Ensembl annotation database for mouse (useMart("ensembl", 
dataset="mmusculus_gene_ensembl")) and human (useMart("ensembl", 
dataset="hsapiens_gene_ensembl")).  
 
The cell cycle database Cyclobase (http://www.cyclebase.org) was used to retrieve and 
identify cell cycle related genes for Paper IV. It is an online database that combines data 
from mRNA expression profiling and quantitative proteomics, but also microscopy-based 
knockdown screens [226].  
 
The method section in Paper IV describes more specific analysis used in this thesis.  
 
 
 
 30 
7 OVERALL AIM 
The overall aim of this thesis focuses on understanding the biological function and clinical 
relevance of the neural transcription factor SOX11 in mantle cell lymphoma and non-
malignant B-cells.  
7.1 SPECIFIC AIMS 
 
Paper I: To define the expression of the SOXC group of transcription factors in MCL and 
non-malignant B-cells, and how the SOX11 gene is epigenetically regulated. 
 
Paper 2: To develop a method for accurate differential diagnosis of lymphoma entities 
similar to MCL by flow cytometry.  
 
Paper 3: To investigate how SOX11 expression levels correlate to clinical parameters and 
if there is a natural cut-off that can be used to define negative cases.  
 
Paper 4: To investigate how SOX11 regulates cell fate and differentiation in early non-
malignant B-cells  
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8 RESULTS AND DISCUSSION 
8.1 PAPER I  
SOXC transcription factors in mantle cell lymphoma: the role of promoter 
methylation in SOX11 expression 
 
Analysis of the relative expression of the SOXC genes, SOX11, SOX4 and SOX12, was 
performed on primary cyclin D1+ MCLs having the t(11;14)(q13;q32) translocation, and in 
non-malignant tissue from tonsil, lymph node and spleen. Out of 29 MCL samples 
examined by IHC, 27 samples could be assessed and 24/27 displayed SOX11 nuclear 
positivity. Non-malignant lymphoid tissue and 3 primary MCLs were negative for SOX11.   
 
Expression levels for the SOXC genes for all 29 samples, non-malignant lymphoid tissue 
and the four MCL cell lines Granta519, Rec1, JeKo-1 and JVM2 were determined by 
qPCR. High SOX11 mRNA levels were detected in all primary MCLs compared to non-
malignant B-cells, except the 3/27 immunohistochemistry in the negative cases, which only 
expressed minute levels. In contrast, expression of SOX4 was variable over the cohort: 
13/29 samples expressed less mRNA than non-malignant B-cells, 6/29 samples similar 
levels of mRNA as non-malignant B-cells and 10/29 higher levels of mRNA than non-
malignant B-cells. We found higher expression of SOX12 in 27/29 samples compared to 
non-malignant B-cells, which was independent on SOX11 status. The expression of SOXC 
varied in the 4 MCL cell lines. In SOX11+ MCLs, the mRNA levels of SOX11 and SOX4 
mRNA, as well as SOX11 and SOX12, significantly correlated (this was only moderate 
when including all MCLs and non-malignant tissues).  
 
The degree of promoter methylation for SOX11 in MCL was investigated by McrBC 
endonuclease digesting of DNA at methylation sites and bisulfite promoter sequencing. 
Both methods demonstrated low levels of promotor methylation for primary MCLs, 
irrespectively of SOX11 status. Thus, within the entity of MCL, there was no correlation 
between SOX11 expression pattern and the methylation status of investigated CpG regions. 
 
After confirming low promoter methylation status, we further established non-promotor 
regulated expression with a demethylating agent, 5-azacitidine (5-AZA). No increase in 
SOX11 expression was observed for Granta519, Rec1, JeKo-1 and JVM2 cells when 
treated over 144 h with 5-AZA. Instead, 5-AZA decreased SOX11 expression by promoter 
methylation independent mechanisms in Granta519 and Rec1 (SOX11+ MCL cell lines). 
The SOX11+ MCL cell lines Granta519, Rec1 and JeKo-1 did not show any change in 
SOX4 mRNA levels. However, SOX4 mRNA levels increased 23-fold for JVM2 (SOX11-). 
The SOX12 mRNA levels remained unchanged for all cell lines. 
 
Discussion 
In Paper I, we investigated the mRNA levels for each member of the group to obtain a 
better understanding of their potential role in MCL. Patients diagnosed as SOX11+ by IHC 
also expressed high levels of mRNA. However, expression of the other SOXC members 
differed. SOX4, expression varied between the different patients compared to SOX12, 
which was overexpressed in most cases. Hitherto SOX12 has not been reported in MCL, but 
since SOX11 and SOX12 compete for the same binding targets with SOX12 having higher 
affinity and lower TAD activity (in vitro) the implication of its expression should be 
investigated. It could be relevant in cases with very high SOX12 expression and potentially 
have an impact in MCL. Even though expression of the two other SOXC genes was 
significantly lower, there is a possibility of co-regulation of the genes in MCL, as their 
expression positively correlated when investigated in all SOX11+ MCLs. Two previous 
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reports have investigated how SOX11 is regulated in MCL (Gustavsson et al. [197] and 
Vegliante et al. [181]). Our results corroborate the results from both of these studies. In the 
context of MCL, the SOX11 promoter region is hypomethylated (independent of SOX11 
status defined by IHC), but not regulated by promotor methylation. Expression is instead 
regulated by histone modification. However, a later study with 42 different cancer cell lines 
(10 MCLs, not methylated) [199] showed that the SOX11 promotor region is variably 
methylated in other types of lymphoma and in cancers. The promotor region was not 
heavily methylated from our McrBC-based and pyrosequencing assays. However, to further 
confirm that SOX11 expression is not regulated via promotor methylation, we treated the 
cells with 5-AZA. As predicted, the mRNA or protein levels of SOX11 did not increase, 
which indicates that the promotor is not methylated. However, mRNA and protein levels 
decreased for two SOX11+ MCL cell lines. Certain toxicity has been reported for the 5-
AZA drug [227], which mechanism might stress the two affected cell lines. Granta519 and 
Rec1 both have wild-type TP53 compared to JeKo-1. In our data, SOX11 mRNA levels did 
not increase by 5-AZA in Raji (SOX11- BL cell line), whereas the histone deacetylase 
(HDAC) inhibitor SAHA induced SOX11 mRNA expression in JVM2 and Raji [181]. From 
our study, we conclude that SOX11 expression is not regulated via promotor methylation. 
Instead, other mechanisms are responsible, most probably by histone modification, but 
potentially also by microRNAs or distant enhancer regions.  
 
Conclusion 
In addition to SOX11, SOX12 is also overexpressed in MCL (independent of SOX11 status 
by IHC). This finding could be of interest as its transactivation activity is lower than that of 
SOX11 and in vitro data [128] suggests that the SOXC proteins, when co-expressed in the 
same cell, compete for the same target genes.  We can further conclude that the SOX11 
promoter region in MCL is hypomethylated in SOX11+ MCL and non-malignant lymphoid 
tissue. The few SOX11- MCLs were heterogeneously methylated, but at low levels. Based 
on these observations, SOX11 gene activation is not regulated by promotor methylation in 
MCL or non-malignant lymphoid tissue.   
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8.2 PAPER II  
Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell 
chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell 
lymphoma 
 
For Paper II, a flow cytometric protocol for intracellular staining of SOX11 was 
developed. The purpose was to be able to integrate this method in a flow cytometry panel 
for lymphoma diagnosis. This would allow for a fast discrimination between MCL and 
other B-cell lymphomas that share a certain morphological and phenotypical overlap, such 
as B-CLL, which do not express SOX11.    
 
In this study, the mouse monoclonal anti-SOX11 MRQ-58 antibody was used in six MCL 
cell lines (Granta519, JeKo-1, JVM2, Rec1, Z138 and Mino) and primary lymphoma cells. 
SOX11 specificity was verified after 24 h transient knockdown by siRNA and subsequent 
detection by WB in two SOX11+ MCL cell lines (Granta519 and Z138). A single band 
between 50 and 75 kDa indicating SOX11 was observed for the non-treated and scrambled 
siRNA-treated samples, whereas the SOX11 siRNA-treated samples had significantly 
reduced levels of the corresponding band. The subcellular localization of SOX11 was 
confirmed to be in the nucleus (highly specific nuclear staining) for the SOX11+ MCL cell 
lines by confocal fluorescent microscopy.  
 
Two different types of permeabilization methods were optimized for Rec1 (the cell line 
with lowest SOX11) expression: Triton X-100 at 0.1% in PBS or saponin 0.1%. The 
saponin permeabilization better preserved FSC/SSC distribution, but Triton X-100 offered 
higher SOX11 staining intensities. A higher fluorescent intensity compared to their isotype 
control staining was observed for SOX11+ cell lines when applying the staining protocol. 
The SOX11- cell line JVM2 was too sensitive for this type of permeabilization and could 
not be included. SOX11 distribution varied for Granta519 (detected by both flow cytometry 
and confocal microscopy). SOX11 expression levels could reliably be quantified using flow 
cytometry with the geometric mean fluorescence intensity (MFI) values for flow cytometry, 
which correlated with the density measurements of the single band detected by WB using 
the MRQ-58 antibody (Pearson's correlation coefficient 0.97, p < 0.007). There was also a 
strong correlation between protein and mRNA levels, analyzed as MFI and 2−∆∆Ct, 
respectively (Spearman's correlation coefficient 0.75, p < 0.001). When applying the 
protocol on B-CLL and MCL primary samples, the MFI was obtained on the monotypic λ 
or κ positive population, whereas SOX11 mRNA levels were based on all mononuclear 
cells isolated from the tissue without enrichment for tumor cells. 
Permeabilization of tumor cells from MCL (12/12 cyclin D1+, 11/12 SOX11+ by 
IHC/ICC) and CLL (8 patients) was successful for all cases. The SOX11 MFI ranged from 
12.6-87.3 in the samples defined as SOX11+ by IHC/ICC, whereas the MFI for the B-CLL 
samples varied between -2.3 and 1.4. The SOX11- MCL sample had a MFI of 2.2. This 
protocol successfully distinguished the MCLs from CLLs based on SOX11 as measured by 
flow cytometric intracellular staining. 
Discussion 
In Paper II, we investigated how well SOX11 could be implemented in a potential clinical 
setting to separate MCL from CLL. Normally, immune phenotyping by flow cytometry can 
discriminate between MCL and CLL (differential expression of surface immunoglobulins 
and the CD79b, CD20, FMC7, CD23 and CD200 markers). However, for certain cases 
there might be phenotypical overlaps, which pose a problem for diagnosis.  
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Since both prognosis and therapy differ between MCL and CLL, a precise diagnosis is of 
clinical importance. Other mature B-cell lymphomas, such as marginal zone lymphomas 
(MZL) may sometimes be CD5+ and thus be difficult to classify by flow cytometry. 
SOX11 is not expressed in CLL, or most other mature B-cell lymphomas, making it a good 
marker for MCL in a flow cytometry panel.  
 
A SOX11 polyclonal antibody was used for detecting SOX11 in Paper I. Recently several 
new antibodies have become available. For this project we used the mouse monoclonal 
MRQ-58 antibody that previously has been shown to have the highest specificity of tested 
SOX11 antibodies (we also validated the antibody by siRNA, our SOX11- cell line JVM2 
and by confocal microscopy for nuclear localization specificity). An advantage with this 
antibody is that it does not to cross-react with the highly similar SOX4 [194] that also could 
be expressed in MCL, as shown in Paper I. SOX11 analysis by flow cytometry correctly 
identified all MCL cell lines and patient samples from the CLL patient samples (also 
negative by IHC). However, the number of cases included was too small to determine a cut-
off level for SOX11-negativity by MFI. SOX11- MCLs will be difficult to differentiate 
from highly similar CLL cases, but that is regardless of method as long as no other 
exclusive markers for the different entities are used. Protein quantification of SOX11 by 
MFI was accurate when correlating to WB intensity, but MFI also correlated to mRNA 
levels. In addition to protein quantification, assessment of SOX11 by flow cytometry also 
allows for a more rapid analysis than IHC. It also permits simultaneous analysis of multiple 
markers allowing further investigation of phenotypical differences within the tumor cell 
populations expressing SOX11.  
 
Conclusion  
This method provides a new diagnostic tool for MCL that allows accurate quantification of 
SOX11 levels. The method is still not used in routine diagnostics due to lack of a 
conjugated SOX11 monoclonal antibody, however, routine labs have asked about details 
regarding the method. Quantifying SOX11 can also be used for several different research 
applications that combine SOX11 expression with phenotypical markers.  
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8.3 PAPER III 
The utility of mRNA analysis in defining SOX11 expression levels in mantle cell 
lymphoma and reactive lymph nodes 
 
To examine how SOX11 mRNA levels correlate to certain clinical parameters, 102 MCL 
cases (lymph node biopsies n=80, tonsils n=6, bone marrow cells n=4, spleens n=3, 
peripheral blood cells n=7, pleural cells n=1 and gastrointestinal biopsy n=1) and 16 
reactive lymph nodes were investigated by qPCR. We further investigated if there is a 
natural SOX11 expression cut-off for defining positive or negative MCL cases by 
comparing qPCR and IHC data from the same patients. 
 
Additionally, the performance of the newly implemented mouse monoclonal anti-SOX11 
MRQ-58 antibody was compared with that of the previously used polyclonal anti-SOX11 
HPA000536 antibody. Several of the cases that were negative with the HPA000536 
antibody turned out to be positive after re-analyzing them with the MRQ-58 antibody. The 
new SOX11 IHC-positivity was more in line with the corresponding mRNA levels for the 
same cases.  
For the 102 MCL cases, the relative fold increase (RFI) of SOX11 ranged from 0.01 to 
7419.41. There was no correlation between tumor cell content and SOX11 RFI values 
(p=0.73). To study any potential clinical significance of low versus high levels of SOX11 
mRNA expression in MCL, samples were grouped based on expression and correlated to 
clinical parameters. Clinical and pathological characteristics for the 10% cases with the 
lowest SOX11 mRNA versus the remaining cases were only significantly different for two 
features, nodal disease (22% in low vs 68% in high, p=0.01) and lymphocytosis (60% in 
low and 16% in high, p=0.005). The quartile of patients with the lowest SOX11 mRNA 
levels had significantly shorter OS in the group of 73 patients who had not received ASCT.  
A potential SOX11 mRNA cut-off level in reactive lymph nodes was examined for 16 
samples, showing a RFI ranging from 1.26 to 58.35. Although significantly lower than for 
all MCLs (p<0.0001), there was no significant difference from the 10% of cases with 
lowest SOX11 mRNA (p=0.24). IHC of the reactive lymph nodes also detected a few small 
SOX11+ cells (6/16) in the mantle zone of CD20+, but cyclin D1- cells. 
The RFI grand mean for MCL samples and reactive lymph nodes was 5.7. Applying this 
criteria, 94/102 MCL samples and 2/16 reactive lymph nodes were above. A RFI above 5.7 
was detected in 1/8 of the SOX11- MCLs (IHC) and 93/94 (98.9%) of the SOX11+ MCLs 
(IHC). Using the above cut-off value resulted in misclassification of only 2/102 by qPCR 
and IHC. However, for the SOX11+ cases by IHC, the qPCR analysis was not able to find a 
natural cut-off that would recognize cases with low expression.  
 
Discussion 
In Paper III, we wanted to investigate how SOX11 expression levels correlated to clinical 
parameters and to define a cut-off value for SOX11- MCL. Knowing how the different 
SOX proteins are able to compete for the same targets, potentially the difference in survival 
reported for SOX11+ MCLs in large cohort studies depends on the actual SOX11 levels in 
the tumor. IHC/ICC studies on large cohorts have been conducted. A weakness of IHC is 
that it is a semi-quantitative technique for quantification and subjective due to interobserver 
variation with no defined cut-offs. Here, we used IHC/ICC as a binary tool (SOX11 +/-) 
and to directly compare our two previously used anti-SOX11 polyclonal HPA000536 
(Paper I) and monoclonal MRQ-58 (Paper II) antibodies with each other and to qPCR. 
Despite the large span among the investigated MCLs (RFI ranged from 0.01 to 7419.41), 
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the RFI values for all SOX11+ MCLs (IHC) were normally distributed. The SOX11 RFI 
could thus not identify a natural cut-off for cases with low RFI. Moreover, there was no 
correlation between tumor cell content and SOX11 RFI. However, among patients who had 
not received ASCT, those with the lowest SOX11 RFI had a significantly shorter OS. Of 
note, the cases were selected based on available material and the patients were not 
uniformly treated. Nonetheless, it is an interesting finding that deviates from the common 
view of SOX11 being an oncogene in MCL. SOX11 also had a reducing effect on 
proliferation/viability in Paper IV, which has been reported for MCL cell lines in some 
studies [187, 197, 228]. The SOX11 RFI low group was not significantly different from that 
of reactive lymph nodes. Using a grand mean for a SOX11 RFI cut-off resulted in a 
discordant classification of only 2/102 MCLs by qPCR and IHC in our study, showing that 
both methods are reliable. An advantage of IHC is the possibility to detect where the 
SOX11+ cells are localized in the tissue, since some of the reactive lymph nodes contained 
a few CD20+ and SOX11+ cells situated in the mantle zones. It also emphasizes the 
importance of scoring SOX11+ only in the tumor area. Finally, we were able to show that 
low SOX11 mRNA levels were significantly associated with less nodal disease and higher 
lymphocytosis compared to high SOX11 mRNA levels. This is in accordance with IHC data 
stating that low SOX11 expression often is associated with non-nodal leukemic disease 
[194]. 
 
Conclusion 
An important finding regarding transcriptional levels of SOX11 is that there seem to be a 
gradient and cut-off when it comes to expression: completely negative, weak, intermediate 
and strong. However, low expression and high expression only correlated to two clinical 
parameters. Nevertheless, applying an agreed SOX11 mRNA cut-off or stratify groups 
based on expression levels could benefit future cohort studies to better compare patients. 
MCLs should only be defined as positive if SOX11 is detected within the tumor region by 
IHC, independently of weak or variable SOX11 expression.    
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8.4 PAPER IV 
Sox11 promotes phenotypical changes and alters the global gene expression pattern in 
pro-B cells 
 
The effect of expressing Sox11 was investigated in non-malignant B-cells. A TetON system 
was used to induce ectopic Sox11 mRNA expression in the IL-3 dependent pro-B cell line 
Ba/F3. SOX11 protein expression in this cellular context clearly influenced cell 
morphology. Expression of Sox11 was induced for 72 h by culture in doxycycline 
supplemented medium (Sox11-ON). During a culture period of 72 h, the cells formed large 
aggregates, which was not observed in their non-induced counterpart (Sox11-OFF) without 
doxycycline.  
 
Viability and proliferation by trypan blue exclusion, XTT, 3H-Thymidine incorporation and 
PI-staining demonstrated significant differences between the Sox11-ON and Sox11-OFF 
cells.  
 
Whole genome expression profiling by microarray after 72 h of Sox11 induction 
demonstrated that the altered phenotype observed in Sox11-ON cells also induced profound 
alterations in gene expression. When comparing Sox11-ON and Sox11-OFF cells, 7980 
genes showed significantly altered transcript levels (FDR q-value ≤ 0.05 and 871 of those 
altered more than 1.5-fold (533 genes up and 338 genes down). The gene showing the 
highest fold change, Mmp8, is involved in proteolysis. Two other highly expressed genes 
were the protocadherin beta genes Pcdhb17 and Pcdhb16. Genes promoting cell 
proliferation and survival were among the more significantly downregulated genes together 
with certain cell adhesion genes.  
 
The leading edge from the Gene Set Enrichment Analysis (GSEA) resulted in 199 enriched 
gene sets for Sox11-ON and 31 enriched gene sets for Sox11-OFF (FDR q-value ≤ 0.05). 
Functions characterizing earlier stages of the cell cycle were attributable to 113/199 gene 
sets with positive enrichment score in Sox11-ON cells, whereas 21/199 gene sets were 
associated with cell cycle stages later than that of the S-phase. The Sox11-OFF cells 
showed a significantly higher enrichment score for metabolic activity (defined by gene sets 
related to lysosome, ribosome, cellular and cation homeostasis). Immune system associated 
gene sets were also significantly downregulated in Sox11-ON cells.  
 
When using genes from Cyclebase 3.0 [226], the Sox11-ON and Sox11-OFF cells 
displayed a significant difference in microarray mean intensity values for genes associated 
with early phases as compared to later phases of the cell cycle. 
 
Sox11 did not evoke significant changes in expression of key genes associated with later 
stages of B-cell differentiation when expressed in Ba/F3 cells. However, the transcript 
levels for two pro-B cell restricted genes Id1 and Tal in Sox11-ON (FDR q-value ≤ 0.05, 
Fold Change: 1.2 and 1.3, respectively) significantly increased upon Sox11 induction.   
 
Gene expression data from sorted murine B-cell populations [229] and Ba/F3 Sox11-
ON/OFF revealed that the gene expression profile of Sox11-ON cells is different from both 
Sox11-OFF and non-transduced Ba/F3 cells as well as cells at other B-cell differentiation 
stages. In spite of large impacts on global gene expression by Sox11, no significant changes 
in expression were observed for key B-cell stage genes. 
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Discussion 
In Paper IV, we investigated the potential role of SOX11 in hematopoiesis or 
lymphopoiesis. SOX4 is important for survival of pro-B cells, but nothing is known about 
SOX11. In MCL, SOX11 has also been suggested to function as an oncogene [188]. 
However, studies regarding the influence of SOX11 on cell proliferation in MCL cell lines 
and tumor growth in xenografts have yielded conflicting results [187, 188]. We found that 
ectopic expression of Sox11 in Ba/F3 pro-B cells is associated with profound phenotypic 
changes resulting in cell aggregation and reduced cell proliferation. When investigating the 
minimal requirement of transforming a healthy murine B-cell to a cancer cell using 
combinations of Myc, BclXL and Bmi1 (a concept developed by Alf Grandien), cells were 
not “immortalized” when replacing any of these genes with different Sox11 constructs (data 
not shown). Instead, we focused on investigating the role of Sox11 in early B-cells. Gene 
expression analysis showed an enrichment of differentially expressed genes associated with 
earlier phases of the cell cycle in Sox11-ON cells. We found that Sox11 expression induced 
homotypic aggregation in Ba/F3 cells, potentially by protocadherin family members. Of 
interest, Pcdhb17 is proposed to block cell migration and reduce cell proliferation [230, 
231] and methylation of PCDHB17 has been correlated with increased risk of relapses and 
higher mortality in BCP ALL [232]. The two genes S100a8 and S100a9 also showed high 
transcript levels in Sox11-ON cells. Consistent with our study, increased adhesion, reduced 
migration and impaired tumor growth and reduced transcript levels of the 
immunomodulatory cytokine CCL3 have been observed when overexpressing 
S100A8/S100A9 in human cervix carcinoma-derived cells [233]. Sell was significantly 
downregulated in Sox11-ON cells; SELL has also been reported to be downregulated in 
MCL (that normally express SOX11) [234]. We showed by functional and gene expression 
data that SOX11 in Ba/F3 cells promote homotypic aggregation and expression of genes 
associated with cell to cell adhesion, rather than genes associated with cell migration. In 
MCL, SOX11 has been suggested to affect B-cell differentiation by decreasing PRDM1 
(encoding for BLIMP1) and BCL6, and increase PAX5 expression, which affected surface 
levels of plasmacytic B-cell markers [188]. We could not detect any significant changes in 
mRNA levels for Pax5, Prdm1 or Bcl6 in response to Sox11 overexpression in Ba/F3 cells. 
This could potentially be because of their distinct cellular background and the function of 
SOX11 can be very context dependent. Reduced proliferation has also been shown after 
overexpressing of SOX11 in MCL cell lines [191, 197], similar to our findings.  
 
Conclusions 
Sox11 was not able to replace any of the minimal genes required to immortalize a healthy 
murine B-cell, indicating that it does not per se act as an oncogene. In early B-cells, the 
transcription factor impacted the morphology and proliferation rate of the cells, but not 
genes associated with B-cell differentiation previously reported. In the context of Ba/F3 
cells, Sox11 may be involved in blockade of B-cell differentiation, but mainly Sox11 seems 
to be involved in pathways that are not directly related to B-cell differentiation. 
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9 CONCLUSIONS   
SOX11 belongs to the highly homologous group of SOXC genes and can act redundantly in 
vitro and in vivo under certain conditions.  
 
From the different experiments and analysis conducted in this thesis, a definite function of 
SOX11 and role in MCL or B-cells remain elusive. The two other SOXC members, SOX4 
and SOX12 are also expressed in MCL, but significantly less. The reason for activating 
SOX11 in MCL is not established, but from this thesis it can be concluded that expression is 
not activated via methylation of its promotor. In both patients and cell lines, the degree of 
promotor methylation is low and demethylating of MCL cells cannot activate expression of 
the gene. Instead it is regulated by histone modification (potentially also microRNAs) in the 
context of MCL.    
 
The use of SOX11 as a highly specific marker for MCL by different methods has been 
demonstrated here by IHC, flow cytometry and qPCR. As SOX11+ by IHC has been 
reported to be associated with both positive and negative clinical outcomes, we quantified 
the levels of SOX11 expression. High expression correlated to longer OS, but there was no 
correlation between the degree of gene expression and clinical parameters that could impact 
survival. We could further show that SOX11 mRNA detection by qPCR and SOX11 protein 
by the gold standard, IHC, corresponded very well.  
 
The idea that SOX11 could have a role as an oncogenic driver was addressed 
experimentally. Sox11 was not found to be a strong oncogenic driver in primary murine B-
cells or when transduced into the progenitor B-cell line Ba/F3. Ba/F3 cells, which are 
themselves not oncogenic, were chosen as a model to investigate the potential effect of 
SOX11 expression in B-cells at the stage of B-cell differentiation at which 
t(11;14)(q13;q32) is thought to occur. In this model, Sox11 did not activate any genes 
implicated in further B-cell differentiation or related to oncogenic potential. We rather 
observed pronounced morphological changes and reduced proliferation. Genes associated 
with adhesion were altered as well as several neural genes, some of which also have been 
reported in MCL. As illustrated in Figure 8, the lack of a coherent gene expression pattern 
when comparing SOX11 knockdown studies in MCL cell lines [187, 188, 201] and 
overexpression of Sox11 in Ba/F3 cells indicates a context dependent function of this 
transcription factor. 
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Figure 8: Intersect between the significantly differentiated genes 
(FDR<0.05) reported for the three above mentioned studies [187, 
188 and 201]. Data plotted in R. 
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9.1 FUTURE PERSPECTIVES 
To delineate the role of SOX11 in the MCL pathogenesis, a more coherent system on 
classifying positive and negative SOX11 MCL is clearly needed. Currently, data from 
different cohorts have used different inclusion criteria, e.g. including nnMCLs and not 
including nnMCLs. Furthermore, a clear definition of nnMCL is lacking. Without this 
information it will be difficult to assess the actual contribution of SOX11 in MCL 
pathogenesis and clinical behavior.    
 
With the new flow cytometry staining procedure for SOX11, different subpopulations 
within MCLs can now be investigated. 
 
SOX11 regulation is known to be associated with histone modification, and now potentially 
a distant enhancer element. Less is known about its actual physical binding partners. For 
SOX proteins in general their binding partners are very important for stabilizing the 
transcriptional complex and thus, their potential for activation and repression of genes. 
Finding out those binding partners in MCL would be of great importance for further 
understanding of the role of SOX11 in MCL.  
 
From this thesis and published data, the function of the SOX11 gene seems to be pluralistic 
and contextual. Depending on expression level, highly similar SOX proteins with different 
functions (activation and repression) have been shown to be able to target the same genes, 
but induce different effect. Highly speculative, but worth to study would be to investigate 
the effect of overexpressing SOX12 in MCL to observe if its expression can interfere with 
SOX11.  
 
To really set-apart the function of SOX11 in MCL cells would be a SOX11-concentration-
dependent experiment that considers both the effects of high expression and low expression 
of the gene in the cells. One way would be the use of an inducible overexpression system 
and an inducible downregulation system for the same cell line where the levels of SOX11 
are titrated up and down, respectively. Different type of cell lines similar to classical (e.g. 
JeKo-1 or Mino) and blastoid (e.g. Granta519 or Z138) MCL should be used. Cells 
experiencing a series of increasing/decreasing SOX11 protein levels would then be 
analyzed by RNA-seq and placed in the context of already known transcriptional targets in 
MCL.      
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